Search

Your search keyword '"Briggs A.H."' showing total 41 results
Start Over Author "Briggs A.H."
41 results on '"Briggs A.H."'

2. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial

Author

Bhatt, D.L., Briggs, A.H., Reed, S.D., Annemans, L., Szarek, M., Bittner, V.A., Diaz, R., Goodman, S.G., Harrington, R.A., Higuchi, K., Joulain, F., Jukema, J.W., Li, Q.H., Mahaffey, K.W., Sanchez, R.J., Roe, M.T., Lopes, R.D., White, H.D., Zeiher, A.M., Schwartz, G.G., Steg, P.G., and ODYSSEY OUTCOMES Investigators

Subjects
Adult, Aged, 80 and over, Male, Cost-Benefit Analysis, Hypercholesterolemia, cholesterol, alirocumab, Cholesterol, LDL, Middle Aged, Antibodies, Monoclonal, Humanized, economic analysis, Treatment Outcome, Double-Blind Method, Humans, Drug Therapy, Combination, Female, acute coronary syndromes, lipids (amino acids, peptides, and proteins), Acute Coronary Syndrome, cost-effectiveness, Aged
Abstract

BACKGROUND Cholesterol reduction with proprotein convertase subtitisin-kexin type 9 inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains uncertain.OBJECTIVES This study sought to determine whether further cholesterol reduction with atirocumab would be cost-effective in patients with a recent acute coronary syndrome on optimal statin therapy.METHODS A cost-effectiveness model leveraging patient-level data from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Atirocumab) was developed to estimate costs and outcomes over a lifetime horizon. Patients (n = 18,924) had a recent acute coronary syndrome and were on high-intensity or maximum-tolerated statin therapy, with a baseline tow-density lipoprotein cholesterol (LDL-C) level >= 70 mg/l, non-high-density lipoprotein cholesterol >= 100 mg/dl, or apotipoprotein B >= 80 mg/l. Atirocumab 75 mg or placebo was administered subcutaneously every 2 weeks. Atirocumab was blindly titrated to 150 mg if LDL-C remained >= 50 mg/dl or switched to placebo if 2 consecutive LDL-C levels were = 100 mg/dl.RESULTS Across the overall population recruited to the ODYSSEY OUTCOMES trial, using an annual treatment cost of US$5,850, the mean overall incremental cost-effectiveness ratio was US$92,200 per QALY (base case). The cost was US$41,800 per QALY in patients with baseline LDL-C >= 100 mg/dl, whereas in those with LDL-C >= 100 mg/dl the cost per QALY was US$299,400. Among patients with LDL-C a100 mg/dl, incremental cost-effectiveness ratios remained below US$100,000 per QALY across a wide variety of sensitivity analyses.CONCLUSIONS In patients with a recent acute coronary syndrome on optimal statin therapy, atirocumab improves cardiovascular outcomes at costs considered intermediate value, with good value in patients with baseline LDL-C mg/dt but less economic value with LDL-C >= 100 mg/dl. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Atirocumab [ODYSSEY OUTCOMES]; NCT01663402) (J Am Colt Cardiol 2020;75:2297-308) (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Published
2020

3. How cost-effective is screening for abdominal aortic aneurysms?

Author

Kim, L.G., Thompson, S.G., Briggs, A.H., Buxton, M.J., and Campbell, H.E.

Subjects
Abdominal aneurysm -- Diagnosis, Medical screening -- Economic aspects, Cost benefit analysis -- Research, Cost benefit analysis, Health, Social sciences
Published
2007

4. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age

Author

Briggs, A.H., Sculpher, M.J., Logan, R.P.H., Aldous, J., Ramsay, M.E., and Baron, J.H.

Subjects
Helicobacter infections -- Diagnosis -- Care and treatment, Cost benefit analysis -- Usage, Indigestion -- Care and treatment -- Diagnosis, Medical screening -- Evaluation -- Usage, Health, Cost benefit analysis, Diagnosis, Evaluation, Care and treatment, Usage
Abstract

Abstract Objective--To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia. Design--A decision analytic model composed of a [...]

Published
1996

5. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Author

Azzabi A., Webb A., Cunningham D., Hickish T., Weaver A., Gollins S., Wasan H.S., Paul J., Robles-Zurita J., Boyd K.A., Briggs A.H., Iveson T., Kerr R.S., Saunders M.P., Cassidy J., Hollander N.H., Tabernero J., Segelov E., Glimelius B., Harkin A., Allan K., McQueen J., Pearson S., Waterston A., Medley L., Wilson C., Ellis R., Essapen S., Dhadda A.S., Hughes R., Falk S., Raouf S., Rees C., Olesen R.K., Propper D., Bridgewater J., Farrugia D., Azzabi A., Webb A., Cunningham D., Hickish T., Weaver A., Gollins S., Wasan H.S., Paul J., Robles-Zurita J., Boyd K.A., Briggs A.H., Iveson T., Kerr R.S., Saunders M.P., Cassidy J., Hollander N.H., Tabernero J., Segelov E., Glimelius B., Harkin A., Allan K., McQueen J., Pearson S., Waterston A., Medley L., Wilson C., Ellis R., Essapen S., Dhadda A.S., Hughes R., Falk S., Raouf S., Rees C., Olesen R.K., Propper D., Bridgewater J., and Farrugia D.

Abstract

BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. METHOD(S): In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. RESULT(S): The 3 M arm is less costly (-4881; 95% CI: -6269; -3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant). CONCLUSION(S): Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care.Copyright © 2018, The Author(s).

Published
2018

6. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

Author

Bousquet, J. Farrell, J. Crooks, G. Hellings, P. Bel, E.H. Bewick, M. Chavannes, N.H. De Sousa, J.C. Cruz, A.A. Haahtela, T. Joos, G. Khaltaev, N. Malva, J. Muraro, A. Nogues, M. Palkonen, S. Pedersen, S. Robalo-Cordeiro, C. Samolinski, B. Strandberg, T. Valiulis, A. Yorgancioglu, A. Zuberbier, T. Bedbrook, A. Aberer, W. Adachi, M. Agusti, A. Akdis, C.A. Akdis, M. Ankri, J. Alonso, A. Annesi-Maesano, I. Ansotegui, I.J. Anto, J.M. Arnavielhe, S. Arshad, H. Bai, C. Baiardini, I. Bachert, C. Baigenzhin, A.K. Barbara, C. Bateman, E.D. Beghé, B. Kheder, A.B. Bennoor, K.S. Benson, M. Bergmann, K.C. Bieber, T. Bindslev-Jensen, C. Bjermer, L. Blain, H. Blasi, F. Boner, A.L. Bonini, M. Bonini, S. Bosnic-Anticevitch, S. Boulet, L.P. Bourret, R. Bousquet, P.J. Braido, F. Briggs, A.H. Brightling, C.E. Brozek, J. Buhl, R. Burney, P.G. Bush, A. Caballero-Fonseca, F. Caimmi, D. Calderon, M.A. Calverley, P.M. Camargos, P.A.M. Canonica, G.W. Camuzat, T. Carlsen, K.H. Carr, W. Carriazo, A. Casale, T. Cepeda Sarabia, A.M. Chatzi, L. Chen, Y.Z. Chiron, R. Chkhartishvili, E. Chuchalin, A.G. Chung, K.F. Ciprandi, G. Cirule, I. Cox, L. Costa, D.J. Custovic, A. Dahl, R. Dahlen, S.E. Darsow, U. De Carlo, G. De Blay, F. Dedeu, T. Deleanu, D. De Manuel Keenoy, E. Demoly, P. Denburg, J.A. Devillier, P. Didier, A. Dinh-Xuan, A.T. Djukanovic, R. Dokic, D. Douagui, H. Dray, G. Dubakiene, R. Durham, S.R. Dykewicz, M.S. El-Gamal, Y. Emuzyte, R. Fabbri, L.M. Fletcher, M. Fiocchi, A. Fink Wagner, A. Fonseca, J. Fokkens, W.J. Forastiere, F. Frith, P. Gaga, M. Gamkrelidze, A. Garces, J. Garcia-Aymerich, J. Gemicioǧlu, B. Gereda, J.E. González Diaz, S. Gotua, M. Grisle, I. Grouse, L. Gutter, Z. Guzmán, M.A. Heaney, L.G. Hellquist-Dahl, B. Henderson, D. Hendry, A. Heinrich, J. Heve, D. Horak, F. Hourihane, J.O.B. Howarth, P. Humbert, M. Hyland, M.E. Illario, M. Ivancevich, J.C. Jardim, J.R. Jares, E.J. Jeandel, C. Jenkins, C. Johnston, S.L. Jonquet, O. Julge, K. Jung, K.S. Just, J. Kaidashev, I.P. Khaitov, M.R. Kalayci, O. Kalyoncu, A.F. Keil, T. Keith, P.K. Klimek, L. Koffi N'Goran, B. Kolek, V. Koppelman, G.H. Kowalski, M.L. Kull, I. Kuna, P. Kvedariene, V. Lambrecht, B. Lau, S. Larenas-Linnemann, D. Laune, D. Le, L.T.T. Lieberman, P. Lipworth, B. Li, J. Lodrup Carlsen, K. Louis, R. MacNee, W. Magard, Y. Magnan, A. Mahboub, B. Mair, A. Majer, I. Makela, M.J. Manning, P. Mara, S. Marshall, G.D. Masjedi, M.R. Matignon, P. Maurer, M. Mavale-Manuel, S. Melén, E. Melo-Gomes, E. Meltzer, E.O. Menzies-Gow, A. Merk, H. Michel, J.P. Miculinic, N. Mihaltan, F. Milenkovic, B. Mohammad, G.M.Y. Molimard, M. Momas, I. Montilla-Santana, A. Morais-Almeida, M. Morgan, M. Mösges, R. Mullol, J. Nafti, S. Namazova-Baranova, L. Naclerio, R. Neou, A. Neffen, H. Nekam, K. Niggemann, B. Ninot, G. Nyembue, T.D. O'Hehir, R.E. Ohta, K. Okamoto, Y. Okubo, K. Ouedraogo, S. Paggiaro, P. Pali-Schöll, I. Panzner, P. Papadopoulos, N. Papi, A. Park, H.S. Passalacqua, G. Pavord, I. Pawankar, R. Pengelly, R. Pfaar, O. Picard, R. Pigearias, B. Pin, I. Plavec, D. Poethig, D. Pohl, W. Popov, T.A. Portejoie, F. Potter, P. Postma, D. Price, D. Rabe, K.F. Raciborski, F. Radier Pontal, F. Repka-Ramirez, S. Reitamo, S. Rennard, S. Rodenas, F. Roberts, J. Roca, J. Rodriguez Mañas, L. Rolland, C. Roman Rodriguez, M. Romano, A. Rosado-Pinto, J. Rosario, N. Rosenwasser, L. Rottem, M. Ryan, D. Sanchez-Borges, M. Scadding, G.K. Schunemann, H.J. Serrano, E. Schmid-Grendelmeier, P. Schulz, H. Sheikh, A. Shields, M. Siafakas, N. Sibille, Y. Similowski, T. Simons, F.E.R. Sisul, J.C. Skrindo, I. Smit, H.A. Solé, D. Sooronbaev, T. Spranger, O. Stelmach, R. Sterk, P.J. Sunyer, J. Thijs, C. To, T. Todo-Bom, A. Triggiani, M. Valenta, R. Valero, A.L. Valia, E. Valovirta, E. Van Ganse, E. Van Hage, M. Vandenplas, O. Vasankari, T. Vellas, B. Vestbo, J. Vezzani, G. Vichyanond, P. Viegi, G. Vogelmeier, C. Vontetsianos, T. Wagenmann, M. Wallaert, B. Walker, S. Wang, D.Y. Wahn, U. Wickman, M. Williams, D.M. Williams, S. Wright, J. Yawn, B.P. Yiallouros, P.K. Yusuf, O.M. Zaidi, A. Zar, H.J. Zernotti, M.E. Zhang, L. Zhong, N. Zidarn, M. Mercier, J.

Published
2017

7. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

Author

Bousquet, J. Schünemann, H.J. Hellings, P.W. Arnavielhe, S. Bachert, C. Bedbrook, A. Bergmann, K.-C. Bosnic-Anticevich, S. Brozek, J. Calderon, M. Canonica, G.W. Casale, T.B. Chavannes, N.H. Cox, L. Chrystyn, H. Cruz, A.A. Dahl, R. De Carlo, G. Demoly, P. Devillier, P. Dray, G. Fletcher, M. Fokkens, W.J. Fonseca, J. Gonzalez-Diaz, S.N. Grouse, L. Keil, T. Kuna, P. Larenas-Linnemann, D. Lodrup Carlsen, K.C. Meltzer, E.O. Mullol, J. Muraro, A. Naclerio, R.N. Palkonen, S. Papadopoulos, N.G. Passalacqua, G. Price, D. Ryan, D. Samolinski, B. Scadding, G.K. Sheikh, A. Spertini, F. Valiulis, A. Valovirta, E. Walker, S. Wickman, M. Yorgancioglu, A. Haahtela, T. Zuberbier, T. Aberer, W. Adachi, M. Agache, I. Akdis, C. Akdis, M. Annesi-Maesano, I. Ansotegui, I.J. Anto, J.M. Arshad, S.H. Baiardini, I. Baigenzhin, A.K. Barbara, C. Bateman, E.D. Beghé, B. Bel, E.H. Ben Kheder, A. Bennoor, K.S. Benson, M. Bernstein, D. Michael, B. Thomas, B. Bindslev-Jensen, C. Bjermer, L. Blain, H. Boner, A. Bonini, M. Bonini, S. Bosse, I. Bouchard, J. Boulet, L.-P. Bourret, R.A. Bousquet, P.J. Braido, F. Briggs, A.H. Brightling, C.E. Buhl, R. Burney, P. Bush, A. Caballero-Fonseca, F. Caimmi, D.P. Camargos, P. Camuzat, T. Carlsen, K.-H. Carr, W. Casale, T.B. Sarabia, A.C. Chatzi, L. Chen, Y. Chiron, R. Chkhartishvili, E. Chuchalin, A. Ciprandi, G. Cirule, I. Correia de Sousa, J. Costa, D. Crooks, G. Custovic, A. Dahlen, S.-E. Darsow, U. De Blay, F. De Manuel Keenoy, E. Dedeu, T. Deleanu, D. Denburg, J. Didier, A. Dinh-Xuan, A.-T. Dokic, D. Douagui, H.B. Dubakiene, R. Durham, S. Dykewicz, M. El-Gamal, Y. Emuzyte, R. Fink-Wagner, A. Fiocchi, A. Forastiere, F. Gamkrelidze, A. Gemicioğlu, B. Gereda, J.E. Gerth van Wijk, R. Gotua, M. Grisle, I. Guzmán, M.A. Haahtela, T. Heinrich, J. Hellquist-Dahl, B. Horak, F. Howarth, P.H. Humbert, M. Hyland, M. Ivancevich, J.-C. Jares, E.J. Johnston, S.L. Jonquet, O. Joos, G. Jung, K.-S. Just, J. Jutel, M. Kaidashev, I.P. Khaitov, M. Kalayci, O. Kalyoncu, F. Keith, P. Khaltaev, N. Kleine-Tebbe, J. Klimek, L. N'Goran, B.K. Kolek, V. Koppelman, G.H. Kowalski, M. Kull, I. Kvedariene, V. Lambrecht, B. Lau, S. Laune, D. Le Thi Tuyet, L. Li, J. Lieberman, P. Lipworth, B.J. Renaud, L. Magard, Y. Magnan, A. Mahboub, B. Majer, I. Makela, M. Manning, P.J. Masjedi, M.R. Maurer, M. Mavale-Manuel, S. Melén, E. Melo-Gomes, E. Mercier, J. Merk, H. Miculinic, N. Mihaltan, F. Milenkovic, B. Mohammad, Y. Molimard, M. Momas, I. Montilla-Santana, A. Morais-Almeida, M. Mösges, R. Nadif, R. Namazova-Baranova, L. Neffen, H. Nekam, K. Neou, A. Niggemann, B. Nyembue, D. O'Hehir, R. Ohta, K. Okamoto, Y. Okubo, K. Ouedraogo, S. Paggiaro, P.-L. Pali-Schöll, I. Palmer, S. Panzner, P. Papi, A. Park, H.-S. Pavord, I. Pawankar, R. Pfaar, O. Picard, R. Pigearias, B. Pin, I. Plavec, D. Pohl, W. Popov, T. Postma, D.S. Potter, P. Poulsen, L.K. Rabe, K.F. Raciborski, F. Pontal, F.R. Reitamo, S. Repka-Ramirez, M.-S. Robalo-Cordeiro, C. Roberts, G. Rodenas, F. Rolland, C. Rodriguez, M.R. Romano, A. Rosado-Pinto, J. Rosario, N.A. Rosenwasser, L. Rottem, M. Sanchez-Borges, M. Sastre-Dominguez, J. Schmid-Grendelmeier, P. Serrano, E. Simons, F.E.R. Sisul, J.-C. Skrindo, I. Smit, H.A. Solé, D. Sooronbaev, T. Spranger, O. Stelmach, R. Strandberg, T. Sunyer, J. Thijs, C. Todo-Bom, A.-M. Triggiani, M. Valenta, R. Valero, A.L. van Hage, M. Vandenplas, O. Vezzani, G. Vichyanond, P. Viegi, G. Wagenmann, M. Wahn, U. De Yun, W. Williams, D. Wright, J. Yawn, B.P. Yiallouros, P. Yusuf, O.M. Zar, H.J. Zernotti, M. Zhang, L. Zhong, N. Zidarn, M.

Abstract

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials. © 2016 The Authors

Published
2016

8. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

Author

Bousquet, J. Hellings, P.W. Agache, I. Bedbrook, A. Bachert, C. Bergmann, K.C. Bewick, M. Bindslev-Jensen, C. Bosnic-Anticevitch, S. Bucca, C. Caimmi, D.P. Camargos, P.A.M. Canonica, G.W. Casale, T. Chavannes, N.H. Cruz, A.A. De Carlo, G. Dahl, R. Demoly, P. Devillier, P. Fonseca, J. Fokkens, W.J. Guldemond, N.A. Haahtela, T. Illario, M. Just, J. Keil, T. Klimek, L. Kuna, P. Larenas-Linnemann, D. Morais-Almeida, M. Mullol, J. Murray, R. Naclerio, R. O'Hehir, R.E. Papadopoulos, N.G. Pawankar, R. Potter, P. Ryan, D. Samolinski, B. Schunemann, H.J. Sheikh, A. Simons, F.E.R. Stellato, C. Todo-Bom, A. Tomazic, P.V. Valiulis, A. Valovirta, E. Ventura, M.T. Wickman, M. Young, I. Yorgancioglu, A. Zuberbier, T. Aberer, W. Akdis, C.A. Akdis, M. Annesi-Maesano, I. Ankri, J. Ansotegui, I.J. Anto, J.M. Arnavielhe, S. Asarnoj, A. Arshad, H. Avolio, F. Baiardini, I. Barbara, C. Barbagallo, M. Bateman, E.D. Beghé, B. Bel, E.H. Bennoor, K.S. Benson, M. Białoszewski, A.Z. Bieber, T. Bjermer, L. Blain, H. Blasi, F. Boner, A.L. Bonini, M. Bonini, S. Bosse, I. Bouchard, J. Boulet, L.P. Bourret, R. Bousquet, P.J. Braido, F. Briggs, A.H. Brightling, C.E. Brozek, J. Buhl, R. Bunu, C. Burte, E. Bush, A. Caballero-Fonseca, F. Calderon, M.A. Camuzat, T. Cardona, V. Carreiro-Martins, P. Carriazo, A.M. Carlsen, K.H. Carr, W. Cepeda Sarabia, A.M. Cesari, M. Chatzi, L. Chiron, R. Chivato, T. Chkhartishvili, E. Chuchalin, A.G. Chung, K.F. Ciprandi, G. De Sousa, J.C. Cox, L. Crooks, G. Custovic, A. Dahlen, S.E. Darsow, U. Dedeu, T. Deleanu, D. Denburg, J.A. De Vries, G. Didier, A. Dinh-Xuan, A.T. Dokic, D. Douagui, H. Dray, G. Dubakiene, R. Durham, S.R. Du Toit, G. Dykewicz, M.S. Eklund, P. El-Gamal, Y. Ellers, E. Emuzyte, R. Farrell, J. Fink Wagner, A. Fiocchi, A. Fletcher, M. Forastiere, F. Gaga, M. Gamkrelidze, A. Gemicioǧlu, B. Gereda, J.E. Van Wick, R.G. González Diaz, S. Grisle, I. Grouse, L. Gutter, Z. Guzmán, M.A. Hellquist-Dahl, B. Heinrich, J. Horak, F. Hourihane, J.O.B. Humbert, M. Hyland, M. Iaccarino, G. Jares, E.J. Jeandel, C. Johnston, S.L. Joos, G. Jonquet, O. Jung, K.S. Jutel, M. Kaidashev, I.P. Khaitov, M. Kalayci, O. Kalyoncu, A.F. Kardas, P. Keith, P.K. Kerkhof, M. Kerstjens, H.A.M. Khaltaev, N. Kogevinas, M. Kolek, V. Koppelman, G.H. Kowalski, M.L. Kuitunen, M. Kull, I. Kvedariene, V. Lambrecht, B. Lau, S. Laune, D. Le, L.T.T. Lieberman, P. Lipworth, B. Li, J. Lodrup Carlsen, K.C. Louis, R. Lupinek, C. MacNee, W. Magar, Y. Magnan, A. Mahboub, B. Maier, D. Majer, I. Malva, J. Manning, P. De Manuel Keenoy, E. Marshall, G.D. Masjedi, M.R. Mathieu-Dupas, E. Maurer, M. Mavale-Manuel, S. Melén, E. Melo-Gomes, E. Meltzer, E.O. Mercier, J. Merk, H. Miculinic, N. Mihaltan, F. Milenkovic, B. Millot-Keurinck, J. Mohammad, Y. Momas, I. Mösges, R. Muraro, A. Namazova-Baranova, L. Nadif, R. Neffen, H. Nekam, K. Nieto, A. Niggemann, B. Nogueira-Silva, L. Nogues, M. Nyembue, T.D. Ohta, K. Okamoto, Y. Okubo, K. Olive-Elias, M. Ouedraogo, S. Paggiaro, P. Pali-Schöll, I. Palkonen, S. Panzner, P. Papi, A. Park, H.S. Passalacqua, G. Pedersen, S. Pereira, A.M. Pfaar, O. Picard, R. Pigearias, B. Pin, I. Plavec, D. Pohl, W. Popov, T.A. Portejoie, F. Postma, D. Poulsen, L.K. Price, D. Rabe, K.F. Raciborski, F. Roberts, G. Robalo-Cordeiro, C. Rodenas, F. Rodriguez-Mañas, L. Rolland, C. Roman Rodriguez, M. Romano, A. Rosado-Pinto, J. Rosario, N. Rottem, M. Sanchez-Borges, M. Sastre-Dominguez, J. Scadding, G.K. Scichilone, N. Schmid-Grendelmeier, P. Serrano, E. Shields, M. Siroux, V. Sisul, J.C. Skrindo, I. Smit, H.A. Solé, D. Sooronbaev, T. Spranger, O. Stelmach, R. Sterk, P.J. Strandberg, T. Sunyer, J. Thijs, C. Triggiani, M. Valenta, R. Valero, A. Van Eerd, M. Van Ganse, E. Van Hague, M. Vandenplas, O. Varona, L.L. Vellas, B. Vezzani, G. Vazankari, T. Viegi, G. Vontetsianos, T. Wagenmann, M. Walker, S. Wang, D.Y. Wahn, U. Werfel, T. Whalley, B. Williams, D.M. Williams, S. Wilson, N. Wright, J. Yawn, B.P. Yiallouros, P.K. Yusuf, O.M. Zaidi, A. Zar, H.J. Zernotti, M.E. Zhang, L. Zhong, N. Zidarn, M.

Abstract

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA - disseminated and implemented in over 70 countries globally - is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease. © 2016 The Author(s).

Published
2016

9. WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3 – Area 5)

Author

Bousquet, J., primary, Farrell, J., additional, Crooks, G., additional, Hellings, P., additional, Bel, E.H., additional, Bewick, M., additional, Chavannes, N.H., additional, Correia de Sousa, J., additional, Cruz, A.A., additional, Haahtela, T., additional, Joos, G., additional, Khaltaev, N., additional, Malva, J., additional, Muraro, A., additional, Nogues, M., additional, Palkonen, S., additional, Pedersen, S., additional, Robalo-Cordeiro, C., additional, Samolinski, B., additional, Strandberg, T., additional, Valiulis, A., additional, Yorgancioglu, A., additional, Zuberbier, T., additional, Bedbrook, A., additional, Aberer, W., additional, Adachi, M., additional, Agusti, A., additional, Akdis, C.A., additional, Akdis, M., additional, Ankri, J., additional, Alonso, A., additional, Annesi-Maesano, I., additional, Ansotegui, I.J., additional, Anto, J.M., additional, Arnavielhe, S., additional, Arshad, H., additional, Bai, C., additional, Baiardini, I., additional, Bachert, C., additional, Baigenzhin, A.K., additional, Barbara, C., additional, Bateman, E.D., additional, Beghé, B., additional, Ben Kheder, A., additional, Bennoor, K.S., additional, Benson, M., additional, Bergmann, K.C., additional, Bieber, T., additional, Bindslev-Jensen, C., additional, Bjermer, L., additional, Blain, H., additional, Blasi, F., additional, Boner, A.L., additional, Bonini, M., additional, Bonini, S., additional, Bosnic-Anticevitch, S., additional, Boulet, L.P., additional, Bourret, R., additional, Bousquet, P.J., additional, Braido, F., additional, Briggs, A.H., additional, Brightling, C.E., additional, Brozek, J., additional, Buhl, R., additional, Burney, P.G., additional, Bush, A., additional, Caballero-Fonseca, F., additional, Caimmi, D., additional, Calderon, M.A., additional, Calverley, P.M., additional, Camargos, P.A.M., additional, Canonica, G.W., additional, Camuzat, T., additional, Carlsen, K.H., additional, Carr, W., additional, Carriazo, A., additional, Casale, T., additional, Cepeda Sarabia, A.M., additional, Chatzi, L., additional, Chen, Y.Z., additional, Chiron, R., additional, Chkhartishvili, E., additional, Chuchalin, A.G., additional, Chung, K.F., additional, Ciprandi, G., additional, Cirule, I., additional, Cox, L., additional, Costa, D.J., additional, Custovic, A., additional, Dahl, R., additional, Dahlen, S.E., additional, Darsow, U., additional, De Carlo, G., additional, De Blay, F., additional, Dedeu, T., additional, Deleanu, D., additional, De Manuel Keenoy, E., additional, Demoly, P., additional, Denburg, J.A., additional, Devillier, P., additional, Didier, A., additional, Dinh-Xuan, A.T., additional, Djukanovic, R., additional, Dokic, D., additional, Douagui, H., additional, Dray, G., additional, Dubakiene, R., additional, Durham, S.R., additional, Dykewicz, M.S., additional, El-Gamal, Y., additional, Emuzyte, R., additional, Fabbri, L.M., additional, Fletcher, M., additional, Fiocchi, A., additional, Fink Wagner, A., additional, Fonseca, J., additional, Fokkens, W.J., additional, Forastiere, F., additional, Frith, P., additional, Gaga, M., additional, Gamkrelidze, A., additional, Garces, J., additional, Garcia-Aymerich, J., additional, Gemicioğlu, B., additional, Gereda, J.E., additional, González Diaz, S., additional, Gotua, M., additional, Grisle, I., additional, Grouse, L., additional, Gutter, Z., additional, Guzmán, M.A., additional, Heaney, L.G., additional, Hellquist-Dahl, B., additional, Henderson, D., additional, Hendry, A., additional, Heinrich, J., additional, Heve, D., additional, Horak, F., additional, Hourihane, J.O’B., additional, Howarth, P., additional, Humbert, M., additional, Hyland, M.E., additional, Illario, M., additional, Ivancevich, J.C., additional, Jardim, J.R., additional, Jares, E.J., additional, Jeandel, C., additional, Jenkins, C., additional, Johnston, S.L., additional, Jonquet, O., additional, Julge, K., additional, Jung, K.S., additional, Just, J., additional, Kaidashev, I., additional, Kaitov, M.R., additional, Kalayci, O., additional, Kalyoncu, A.F., additional, Keil, T., additional, Keith, P.K., additional, Klimek, L., additional, Koffi N’Goran, B., additional, Kolek, V., additional, Koppelman, G.H., additional, Kowalski, M.L., additional, Kull, I., additional, Kuna, P., additional, Kvedariene, V., additional, Lambrecht, B., additional, Lau, S., additional, Larenas-Linnemann, D., additional, Laune, D., additional, Le, L.T.T., additional, Lieberman, P., additional, Lipworth, B., additional, Li, J., additional, Lodrup Carlsen, K., additional, Louis, R., additional, MacNee, W., additional, Magard, Y., additional, Magnan, A., additional, Mahboub, B., additional, Mair, A., additional, Majer, I., additional, Makela, M.J., additional, Manning, P., additional, Mara, S., additional, Marshall, G.D., additional, Masjedi, M.R., additional, Matignon, P., additional, Maurer, M., additional, Mavale-Manuel, S., additional, Melén, E., additional, Melo-Gomes, E., additional, Meltzer, E.O., additional, Menzies-Gow, A., additional, Merk, H., additional, Michel, J.P., additional, Miculinic, N., additional, Mihaltan, F., additional, Milenkovic, B., additional, Moda Y. Mohammad, G., additional, Molimard, M., additional, Momas, I., additional, Montilla-Santana, A., additional, Morais-Almeida, M., additional, Morgan, M., additional, Mösges, R., additional, Mullol, J., additional, Nafti, S., additional, Namazova-Baranova, L., additional, Naclerio, R., additional, Neou, A., additional, Neffen, H., additional, Nekam, K., additional, Niggemann, B., additional, Ninot, G., additional, Nyembue, T.D., additional, O’Hehir, R.E., additional, Ohta, K., additional, Okamoto, Y., additional, Okubo, K., additional, Ouedraogo, S., additional, Paggiaro, P., additional, Pali-Schöll, I., additional, Panzner, P., additional, Papadopoulos, N., additional, Papi, A., additional, Park, H.S., additional, Passalacqua, G., additional, Pavord, I., additional, Pawankar, R., additional, Pengelly, R., additional, Pfaar, O., additional, Picard, R., additional, Pigearias, B., additional, Pin, I., additional, Plavec, D., additional, Poethig, D., additional, Pohl, W., additional, Popov, T.A., additional, Portejoie, F., additional, Potter, P., additional, Postma, D., additional, Price, D., additional, Rabe, K.F., additional, Raciborski, F., additional, Radier Pontal, F., additional, Repka-Ramirez, S., additional, Reitamo, S., additional, Rennard, S., additional, Rodenas, F., additional, Roberts, J., additional, Roca, J., additional, Rodriguez Mañas, L., additional, Rolland, C., additional, Roman Rodriguez, M., additional, Romano, A., additional, Rosado-Pinto, J., additional, Rosario, N., additional, Rosenwasser, L., additional, Rottem, M., additional, Ryan, D., additional, Sanchez-Borges, M., additional, Scadding, G.K., additional, Schunemann, H.J., additional, Serrano, E., additional, Schmid-Grendelmeier, P., additional, Schulz, H., additional, Sheikh, A., additional, Shields, M., additional, Siafakas, N., additional, Sibille, Y., additional, Similowski, T., additional, Simons, F.E.R., additional, Sisul, J.C., additional, Skrindo, I., additional, Smit, H.A., additional, Solé, D., additional, Sooronbaev, T., additional, Spranger, O., additional, Stelmach, R., additional, Sterk, P.J., additional, Sunyer, J., additional, Thijs, C., additional, To, T., additional, Todo-Bom, A., additional, Triggiani, M., additional, Valenta, R., additional, Valero, A.L., additional, Valia, E., additional, Valovirta, E., additional, Van Ganse, E., additional, van Hage, M., additional, Vandenplas, O., additional, Vasankari, T., additional, Vellas, B., additional, Vestbo, J., additional, Vezzani, G., additional, Vichyanond, P., additional, Viegi, G., additional, Vogelmeier, C., additional, Vontetsianos, T., additional, Wagenmann, M., additional, Wallaert, B., additional, Walker, S., additional, Wang, D.Y., additional, Wahn, U., additional, Wickman, M., additional, Williams, D.M., additional, Williams, S., additional, Wright, J., additional, Yawn, B.P., additional, Yiallouros, P.K., additional, Yusuf, O.M., additional, Zaidi, A., additional, Zar, H.J., additional, Zernotti, M.E., additional, Zhang, L., additional, Zhong, N., additional, Zidarn, M., additional, and Mercier, J., additional

Published
2017
Full Text
View/download PDF

10. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation

Author

Bousquet, J. Schunemann, H.J. Fonseca, J. Samolinski, B. Bachert, C. Canonica, G.W. Casale, T. Cruz, A.A. Demoly, P. Hellings, P. Valiulis, A. Wickman, M. Zuberbier, T. Bosnic-Anticevitch, S. Bedbrook, A. Bergmann, K.C. Caimmi, D. Dahl, R. Fokkens, W.J. Grisle, I. Lodrup Carlsen, K. Mullol, J. Muraro, A. Palkonen, S. Papadopoulos, N. Passalacqua, G. Ryan, D. Valovirta, E. Yorgancioglu, A. Aberer, W. Agache, I. Adachi, M. Akdis, C.A. Akdis, M. Annesi-Maesano, I. Ansotegui, I.J. Anto, J.M. Arnavielhe, S. Arshad, H. Baiardini, I. Baigenzhin, A.K. Barbara, C. Bateman, E.D. Beghé, B. Bel, E.H. Ben Kheder, A. Bennoor, K.S. Benson, M. Bewick, M. Bieber, T. Bindslev-Jensen, C. Bjermer, L. Blain, H. Boner, A.L. Boulet, L.P. Bonini, M. Bonini, S. Bosse, I. Bourret, R. Bousquet, P.J. Braido, F. Briggs, A.H. Brightling, C.E. Brozek, J. Buhl, R. Burney, P.G. Bush, A. Caballero-Fonseca, F. Calderon, M.A. Camargos, P.A.M. Camuzat, T. Carlsen, K.H. Carr, W. Cepeda Sarabia, A.M. Chavannes, N.H. Chatzi, L. Chen, Y.Z. Chiron, R. Chkhartishvili, E. Chuchalin, A.G. Ciprandi, G. Cirule, I. Correia De Sousa, J. Cox, L. Crooks, G. Costa, D.J. Custovic, A. Dahlen, S.E. Darsow, U. De Carlo, G. De Blay, F. Dedeu, T. Deleanu, D. Denburg, J.A. Devillier, P. Didier, A. Dinh-Xuan, A.T. Dokic, D. Douagui, H. Dray, G. Dubakiene, R. Durham, S.R. Dykewicz, M.S. El-Gamal, Y. Emuzyte, R. Fink Wagner, A. Fletcher, M. Fiocchi, A. Forastiere, F. Gamkrelidze, A. Gemicioʇlu, B. Gereda, J.E. González Diaz, S. Gotua, M. Grouse, L. Guzmán, M.A. Haahtela, T. Hellquist-Dahl, B. Heinrich, J. Horak, F. Hourihane, J.O.B. Howarth, P. Humbert, M. Hyland, M.E. Ivancevich, J.C. Jares, E.J. Johnston, S.L. Joos, G. Jonquet, O. Jung, K.S. Just, J. Kaidashev, I.P. Kalayci, O. Kalyoncu, A.F. Keil, T. Keith, P.K. Khaltaev, N. Klimek, L. Koffi N'Goran, B. Kolek, V. Koppelman, G.H. Kowalski, M.L. Kull, I. Kuna, P. Kvedariene, V. Lambrecht, B. Lau, S. Larenas-Linnemann, D. Laune, D. Le, L.T.T. Lieberman, P. Lipworth, B. Li, J. Louis, R. Magard, Y. Magnan, A. Mahboub, B. Majer, I. Makela, M.J. Manning, P. De Manuel Keenoy, E. Marshall, G.D. Masjedi, M.R. Maurer, M. Mavale-Manuel, S. Melén, E. Melo-Gomes, E. Meltzer, E.O. Merk, H. Miculinic, N. Mihaltan, F. Milenkovic, B. Mohammad, Y. Molimard, M. Momas, I. Montilla-Santana, A. Morais-Almeida, M. Mösges, R. Namazova-Baranova, L. Naclerio, R. Neou, A. Neffen, H. Nekam, K. Niggemann, B. Nyembue, T.D. O'Hehir, R.E. Ohta, K. Okamoto, Y. Okubo, K. Ouedraogo, S. Paggiaro, P. Pali-Schöll, I. Palmer, S. Panzner, P. Papi, A. Park, H.S. Pavord, I. Pawankar, R. Pfaar, O. Picard, R. Pigearias, B. Pin, I. Plavec, D. Pohl, W. Popov, T.A. Portejoie, F. Postma, D. Potter, P. Price, D. Rabe, K.F. Raciborski, F. Radier Pontal, F. Repka-Ramirez, S. Robalo-Cordeiro, C. Rolland, C. Rosado-Pinto, J. Reitamo, S. Rodenas, F. Roman Rodriguez, M. Romano, A. Rosario, N. Rosenwasser, L. Rottem, M. Sanchez-Borges, M. Scadding, G.K. Serrano, E. Schmid-Grendelmeier, P. Sheikh, A. Simons, F.E.R. Sisul, J.C. Skrindo, I. Smit, H.A. Solé, D. Sooronbaev, T. Spranger, O. Stelmach, R. Strandberg, T. Sunyer, J. Thijs, C. Todo-Bom, A. Triggiani, M. Valenta, R. Valero, A.L. Van Hage, M. Vandenplas, O. Vezzani, G. Vichyanond, P. Viegi, G. Wagenmann, M. Walker, S. Wang, D.Y. Wahn, U. Williams, D.M. Wright, J. Yawn, B.P. Yiallouros, P.K. Yusuf, O.M. Zar, H.J. Zernotti, M.E. Zhang, L. Zhong, N. Zidarn, M. Mercier, J.

Abstract

Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards. © 2015 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2015

11. WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3 – Area 5)

Author

Bousquet, J., Farrell, J., Crooks, G., Hellings, P., Bel, E.H., Bewick, M., Chavannes, N.H., Correia de Sousa, J., Cruz, A.A., Haahtela, T., Joos, G., Khaltaev, N., Malva, J., Muraro, A., Nogues, M., Palkonen, S., Pedersen, S., Robalo-Cordeiro, C., Samolinski, B., Strandberg, T., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Bedbrook, A., Aberer, W., Adachi, M., Agusti, A., Akdis, C.A., Akdis, M., Ankri, J., Alonso, A., Annesi-Maesano, I., Ansotegui, I.J., Anto, J.M., Arnavielhe, S., Arshad, H., Bai, C., Baiardini, I., Bachert, C., Baigenzhin, A.K., Barbara, C., Bateman, E.D., Beghé, B., Ben Kheder, A., Bennoor, K.S., Benson, M., Bergmann, K.C., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Boner, A.L., Bonini, M., Bonini, S., Bosnic-Anticevitch, S., Boulet, L.P., Bourret, R., Bousquet, P.J., Braido, F., Briggs, A.H., Brightling, C.E., Brozek, J., Buhl, R., Burney, P.G., Bush, A., Caballero-Fonseca, F., Caimmi, D., Calderon, M.A., Calverley, P.M., Camargos, P.A.M., Canonica, G.W., Camuzat, T., Carlsen, K.H., Carr, W., Carriazo, A., Casale, T., Cepeda Sarabia, A.M., Chatzi, L., Chen, Y.Z., Chiron, R., Chkhartishvili, E., Chuchalin, A.G., Chung, K.F., Ciprandi, G., Cirule, I., Cox, L., Costa, D.J., Custovic, A., Dahl, R., Dahlen, S.E., Darsow, U., De Carlo, G., De Blay, F., Dedeu, T., Deleanu, D., De Manuel Keenoy, E., Demoly, P., Denburg, J.A., Devillier, P., Didier, A., Dinh-Xuan, A.T., Djukanovic, R., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S.R., Dykewicz, M.S., El-Gamal, Y., Emuzyte, R., Fabbri, L.M., Fletcher, M., Fiocchi, A., Fink Wagner, A., Fonseca, J., Fokkens, W.J., Forastiere, F., Frith, P., Gaga, M., Gamkrelidze, A., Garces, J., Garcia-Aymerich, J., Gemicioğlu, B., Gereda, J.E., González Diaz, S., Gotua, M., Grisle, I., Grouse, L., Gutter, Z., Guzmán, M.A., Heaney, L.G., Hellquist-Dahl, B., Henderson, D., Hendry, A., Heinrich, J., Heve, D., Horak, F., Hourihane, J.O’B., Howarth, P., Humbert, M., Hyland, M.E., Illario, M., Ivancevich, J.C., Jardim, J.R., Jares, E.J., Jeandel, C., Jenkins, C., Johnston, S.L., Jonquet, O., Julge, K., Jung, K.S., Just, J., Kaidashev, I., Kaitov, M.R., Kalayci, O., Kalyoncu, A.F., Keil, T., Keith, P.K., Klimek, L., Koffi N’Goran, B., Kolek, V., Koppelman, G.H., Kowalski, M.L., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Lau, S., Larenas-Linnemann, D., Laune, D., Le, L.T.T., Lieberman, P., Lipworth, B., Li, J., Lodrup Carlsen, K., Louis, R., MacNee, W., Magard, Y., Magnan, A., Mahboub, B., Mair, A., Majer, I., Makela, M.J., Manning, P., Mara, S., Marshall, G.D., Masjedi, M.R., Matignon, P., Maurer, M., Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E.O., Menzies-Gow, A., Merk, H., Michel, J.P., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda Y. Mohammad, G., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Morgan, M., Mösges, R., Mullol, J., Nafti, S., Namazova-Baranova, L., Naclerio, R., Neou, A., Neffen, H., Nekam, K., Niggemann, B., Ninot, G., Nyembue, T.D., O’Hehir, R.E., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Panzner, P., Papadopoulos, N., Papi, A., Park, H.S., Passalacqua, G., Pavord, I., Pawankar, R., Pengelly, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Poethig, D., Pohl, W., Popov, T.A., Portejoie, F., Potter, P., Postma, D., Price, D., Rabe, K.F., Raciborski, F., Radier Pontal, F., Repka-Ramirez, S., Reitamo, S., Rennard, S., Rodenas, F., Roberts, J., Roca, J., Rodriguez Mañas, L., Rolland, C., Roman Rodriguez, M., Romano, A., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Ryan, D., Sanchez-Borges, M., Scadding, G.K., Schunemann, H.J., Serrano, E., Schmid-Grendelmeier, P., Schulz, H., Sheikh, A., Shields, M., Siafakas, N., Sibille, Y., Similowski, T., Simons, F.E.R., Sisul, J.C., Skrindo, I., Smit, H.A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sterk, P.J., Sunyer, J., Thijs, C., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A.L., Valia, E., Valovirta, E., Van Ganse, E., van Hage, M., Vandenplas, O., Vasankari, T., Vellas, B., Vestbo, J., Vezzani, G., Vichyanond, P., Viegi, G., Vogelmeier, C., Vontetsianos, T., Wagenmann, M., Wallaert, B., Walker, S., Wang, D.Y., Wahn, U., Wickman, M., Williams, D.M., Williams, S., Wright, J., Yawn, B.P., Yiallouros, P.K., Yusuf, O.M., Zaidi, A., Zar, H.J., Zernotti, M.E., Zhang, L., Zhong, N., Zidarn, M., and Mercier, J.

Abstract

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.

Published
2024
Full Text
View/download PDF

12. A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation

Author

Lewsey, J.D., Lawson, K.D., Ford, I., Fox, K.A.A., Ritchie, L.D., Tunstall-Pedoe, H., Watt, G.C.M., Woodward, M., Kent, S., Neilson, M., and Briggs, A.H.

Abstract

Objectives: A policy model is a model that can evaluate the effectiveness and cost-effectiveness of interventions and inform policy decisions. In this study, we introduce a cardiovascular disease (CVD) policy model which can be used to model remaining life expectancy including a measure of socioeconomic deprivation as an independent risk factor for CVD.\ud \ud Design: A state transition model was developed using the Scottish Heart Health Extended Cohort (SHHEC) linked to Scottish morbidity and death records. Individuals start in a CVD-free state and can transit to three CVD event states plus a non-CVD death state. Individuals who have a non-fatal first event are then followed up until death. Taking a competing risk approach, the cause-specific hazards of a first event are modelled using parametric survival analysis. Survival following a first non-fatal event is also modelled parametrically. We assessed discrimination, validation and calibration of our model.\ud \ud Results: Our model achieved a good level of discrimination in each component (c-statistics for men (women)—non-fatal coronary heart disease (CHD): 0.70 (0.74), non-fatal cerebrovascular disease (CBVD): 0.73 (0.76), fatal CVD: 0.77 (0.80), fatal non-CVD: 0.74 (0.72), survival after non-fatal CHD: 0.68 (0.67) and survival after non-fatal CBVD: 0.65 (0.66)). In general, our model predictions were comparable with observed event rates for a Scottish randomised statin trial population which has an overlapping follow-up period with SHHEC. After applying a calibration factor, our predictions of life expectancy closely match those published in recent national life tables.\ud \ud Conclusions: Our model can be used to estimate the impact of primary prevention interventions on life expectancy and can assess the impact of interventions on inequalities.

Published
2014

13. A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme

Author

Tigbe, W.W., Briggs, A.H., and Lean, M.E.J.

Abstract

Background: Previous studies, based on relative risks for certain secondary diseases, have shown greater healthcare costs in higher body mass index (BMI) categories. The present study quantifies the relationship between BMI and total healthcare expenditure, with the patient as the unit of analysis.\ud \ud Methods: Analyses of cross-sectional data, collected over 18-months in 2002–2003, from 3324 randomly selected patients, in 65 general practices across UK. Healthcare costs estimated from primary care, outpatient, accident/emergency and hospitalisation attendances, weighted by unit costs taken from standard sources.\ud \ud Results: In univariate analyses, significant associations (Pmen, drinkernon-smokers, and increasing with greater physical activity, age and BMI. In multivariate analysis, age, sex, BMI, smoking and alcohol consumption remained significantly associated with healthcare cost, and together explained just 9% of the variance in healthcare expenditure. Adjusted total annual healthcare cost was £16 (95% CI £11–£21) higher per unit BMI. All cost categories were significantly (P40 compared with BMI \ud \ud Conclusions: Annual healthcare expenditure rose a mean of £16 per unit greater BMI, doubling between BMI 20–40 kg m−2. This gradient may be an underestimate if the lower-BMI patients with heights and weights recorded had other costly diseases.

Published
2013

14. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

Author

Bousquet, J. Schünemann, H.J. Samolinski, B. Demoly, P. Baena-Cagnani, C.E. Bachert, C. Bonini, S. Boulet, L.P. Bousquet, P.J. Brozek, J.L. Canonica, G.W. Casale, T.B. Cruz, A.A. Fokkens, W.J. Fonseca, J.A. Van Wijk, R.G. Grouse, L. Haahtela, T. Khaltaev, N. Kuna, P. Lockey, R.F. Lodrup Carlsen, K.C. Mullol, J. Naclerio, R. O'hehir, R.E. Ohta, K. Palkonen, S. Papadopoulos, N.G. Passalacqua, G. Pawankar, R. Price, D. Ryan, D. Simons, F.E.R. Togias, A. Williams, D. Yorgancioglu, A. Yusuf, O.M. Aberer, W. Adachi, M. Agache, I. Aït-Khaled, N. Akdis, C.A. Andrianarisoa, A. Annesi-Maesano, I. Ansotegui, I.J. Baiardini, I. Bateman, E.D. Bedbrook, A. Beghé, B. Beji, M. Bel, E.H. Ben Kheder, A. Bennoor, K.S. Bergmann, K.C. Berrissoul, F. Bieber, T. Bindslev Jensen, C. Blaiss, M.S. Boner, A.L. Bouchard, J. Braido, F. Brightling, C.E. Bush, A. Caballero, F. Calderon, M.A. Calvo, M.A. Camargos, P.A.M. Caraballo, L.R. Carlsen, K.H. Carr, W. Cepeda, A.M. Cesario, A. Chavannes, N.H. Chen, Y.Z. Chiriac, A.M. Chivato Pérez, T. Chkhartishvili, E. Ciprandi, G. Costa, D.J. Cox, L. Custovic, A. Dahl, R. Darsow, U. De Blay, F. Deleanu, D. Denburg, J.A. Devillier, P. Didi, T. Dokic, D. Dolen, W.K. Douagui, H. Dubakiene, R. Durham, S.R. Dykewicz, M.S. El-Gamal, Y. El-Meziane, A. Emuzyte, R. Fiocchi, A. Fletcher, M. Fukuda, T. Gamkrelidze, A. Gereda, J.E. González Diaz, S. Gotua, M. Guzmán, M.A. Hellings, P.W. Hellquist-Dahl, B. Horak, F. Hourihane, J.O'B. Howarth, P. Humbert, M. Ivancevich, J.C. Jackson, C. Just, J. Kalayci, O. Kaliner, M.A. Kalyoncu, A.F. Keil, T. Keith, P.K. Khayat, G. Kim, Y.Y. Koffi N'Goran, B. Koppelman, G.H. Kowalski, M.L. Kull, I. Kvedariene, V. Larenas-Linnemann, D. Le, L.T. Lemière, C. Li, J. Lieberman, P. Lipworth, B. Mahboub, B. Makela, M.J. Martin, F. Marshall, G.D. Martinez, F.D. Masjedi, M.R. Maurer, M. Mavale-Manuel, S. Mazon, A. Melen, E. Meltzer, E.O. Mendez, N.H. Merk, H. Mihaltan, F. Mohammad, Y. Morais-Almeida, M. Muraro, A. Nafti, S. Namazova-Baranova, L. Nekam, K. Neou, A. Niggemann, B. Nizankowska-Mogilnicka, E. Nyembue, T.D. Okamoto, Y. Okubo, K. Orru, M.P. Ouedraogo, S. Ozdemir, C. Panzner, P. Pali-Schöll, I. Park, H.S. Pigearias, B. Pohl, W. Popov, T.A. Postma, D.S. Potter, P. Rabe, K.F. Ratomaharo, J. Reitamo, S. Ring, J. Roberts, R. Rogala, B. Romano, A. Roman Rodriguez, M. Rosado-Pinto, J. Rosenwasser, L. Rottem, M. Sanchez-Borges, M. Scadding, G.K. Schmid-Grendelmeier, P. Sheikh, A. Sisul, J.C. Solé, D. Sooronbaev, T. Spicak, V. Spranger, O. Stein, R.T. Stoloff, S.W. Sunyer, J. Szczeklik, A. Todo-Bom, A. Toskala, E. Tremblay, Y. Valenta, R. Valero, A.L. Valeyre, D. Valiulis, A. Valovirta, E. Van Cauwenberge, P. Vandenplas, O. Van Weel, C. Vichyanond, P. Viegi, G. Wang, D.Y. Wickman, M. Wöhrl, S. Wright, J. Yawn, B.P. Yiallouros, P.K. Zar, H.J. Zernotti, M.E. Zhong, N. Zidarn, M. Zuberbier, T. Ang, C.S. Baigenzhin, A.K. Boakye, D.A. Briggs, A.H. Burney, P.G. Busse, W.W. Chuchalin, A.G. Haddad, H. Johnston, S.L. Kogevinas, M. Levy, M.L. Mohammadi, A. Oddie, S. Rezagui, D. Terreehorst, I. Warner, J.O.

Abstract

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. © 2012 American Academy of Allergy, Asthma & Immunology.

Published
2012

15. Nurse led versus lay educators support for those with asthma in primary care: a costing study

Author

Roberts, N.J., Boyd, K., Briggs, A.H., Caress, A.L., and Partridge, M.R.

Subjects
health care economics and organizations
Abstract

Background - Regular review and support for asthma self-management is promoted in guidelines. A randomised controlled trial suggested that unscheduled health care usage was similar when patients were offered self management support by a lay-trainer or practice nurses.\ud \ud Methods - Following the RCT, a costing study was undertaken using the trial data to account for the cost of delivery of the service under both strategies and the resulting impact on unscheduled healthcare (measure of effectiveness) in this trial.\ud \ud Results - One year data (n = 418) showed that 29% (61/205) of the nurse group required unscheduled healthcare (177 events) compared with 30.5% (65/213) for lay-trainers (178 events).\ud \ud The training costs for the lay-trainers were greater than nurses (£36 versus £18 respectively per patient, p\ud \ud Conclusions - There were no significant differences in the cost of training and healthcare delivery between nurse and lay trainers, and no significant difference in the cost of unscheduled health care use.

Published
2012

16. Modeling good research practices - overview: a report of the ISPOR-SMDM modeling good research practices task force - 1

Author

Caro, J.J., Briggs, A.H., Siebert, U., and Kuntz, K.M.

Abstract

Models—mathematical frameworks that facilitate estimation of the consequences of health care decisions—have become essential tools for health technology assessment. Evolution of the methods since the first ISPOR modeling task force reported in 2003 has led to a new task force, jointly convened with the Society for Medical Decision Making, and this series of seven papers presents the updated recommendations for best practices in conceptualizing models; implementing state–transition approaches, discrete event simulations, or dynamic transmission models; dealing with uncertainty; and validating and reporting models transparently. This overview introduces the work of the task force, provides all the recommendations, and discusses some quandaries that require further elucidation. The audience for these papers includes those who build models, stakeholders who utilize their results, and, indeed, anyone concerned with the use of models to support decision making.

Published
2012

17. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: An ARIA-GA2LEN statement

Author

Bousquet, J. Schünemann, H.J. Bousquet, P.J. Bachert, C. Canonica, G.W. Casale, T.B. Demoly, P. Durham, S. Carlsen, K.-H. Malling, H.-J. Passalacqua, G. Simons, F.E.R. Anto, J. Baena-Cagnani, C.E. Bergmann, K.-C. Bieber, T. Briggs, A.H. Brozek, J. Calderon, M.A. Dahl, R. Devillier, P. Gerth Van Wijk, R. Howarth, P. Larenas, D. Papadopoulos, N.G. Schmid-Grendelmeier, P. Zuberbier, T.

Abstract

Specific immunotherapy (SIT) is one of the treatments for allergic rhinitis. However, for allergists, nonspecialists, regulators, payers, and patients, there remain gaps in understanding the evaluation of randomized controlled trials (RCTs). Although treating the same diseases, RCTs in SIT and pharmacotherapy should be considered separately for several reasons, as developed in this study. These include the severity and persistence of allergic rhinitis in the patients enrolled in the study, the problem of the placebo, allergen exposure (in particular pollen and mite), the analysis and reporting of the study, the level of symptoms of placebo-treated patients, the clinical relevance of the efficacy of SIT, the need for a validated combined symptom-medication score, the differences between children and adults and pharmacoeconomic analyses. This statement reviews issues raised by the interpretation of RCTs in sublingual immunotherapy. It is not possible to directly extrapolate the rules or parameters used in medication RCTs to SIT. It also provides some suggestions for the research that will be needed. Interestingly, some of the research questions can be approached with the available data obtained from large RCTs. © 2011 John Wiley & Sons A/S.

Published
2011

19. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

Author

Briggs, A.H., Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D., and Burge, S.

Subjects
RA, HG
Abstract

Objectives: To explore the cost-effectiveness of fluticasone propionate (FP) for the treatment of chronic obstructive pulmonary disease (COPD), we estimated costs and quality-adjusted life-years (QALYs) over 3 years, based on an economic appraisal of a previously reported clinical trial (Inhaled Steroids in Obstructive Lung Disease in Europe [ISOLDE]).\ud \ud Methods: Seven hundred forty-two patients enrolled in the ISOLDE trial who received either FP or placebo had data available on health-care costs and quality of life over the period of the study. The SF-36-based utility scores for quality of life were used to calculate QALYs. A combined imputation and bootstrapping procedure was employed to handle missing data and to estimate statistical uncertainty in the estimated cumulative costs and QALYs over the study period. The imputation approach was based on propensity scoring and nesting this approach within the bootstrap ensured that multiple imputations were performed such that statistical estimates included imputation uncertainty.\ud \ud Results: Complete data were available on mortality within the follow-up period of the study and a nonsignificant trend toward improved survival of 0.06 (95% confidence interval [CI] –0.01 to 0.15) life-years was observed. In an analysis based on a propensity scoring approach to missing data we estimated the incremental costs of FP versus placebo to be £1021 (95% CI £619–1338) with an additional effect of 0.11 QALYs (CI 0.04–0.20). Cost-effectiveness estimates for the within-trial period of £17,700 per life-year gained (£6900 to ∞) and £9500 per QALY gained (CI £4300–26,500) were generated that include uncertainty due to the imputation process. An alternative imputation approach did not materially affect these estimates.\ud \ud Conclusions: Previous analyses of the ISOLDE study showed significant improvement on disease-specific health status measures and a trend toward a survival advantage for treatment with FP. This analysis shows that joint considerations of quality of life and survival result in a substantial increase in QALYs favoring treatment with FP. Based on these data, the inhaled corticosteroid FP appears cost-effective for the treatment of COPD. Confirmation or refutation of this result may be achieved once the Towards a Revolution in COPD Health (TORCH) study reports, a large randomized controlled trial powered to detect mortality changes associated with the use of FP alone, or in combination with salmeterol, which is also collecting resource use and utility data suitable for estimating cost-effectiveness.

Published
2006

21. A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results

Author

Reed, S.D., Dillingham, P.W., Briggs, A.H., Veestra, D.L., and Sullivan, S.D.

Subjects
RA, health care economics and organizations, HJ
Abstract

Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making. To address this concern, many committees undertake site-specific economic evaluations, which are often limited by small sample sizes and nonrandomized designs. We show how 2 complementary approaches were used to minimize these limitations in an economic evaluation of abciximab at 1 institution. Using a propensity score methodology, we selected patients who did not receive abciximab for the comparison cohort. Then, we adopted a Bayesian, hierarchical, random-effects model to integrate site-specific and clinical trial data. We applied the posterior distributions of effectiveness with local cost data in a traditional decision-analytic model. In 74% of the simulations, abciximab was cost-effective at 1 institution at the $50,000 per life year saved threshold, assuming a 50:50 split of patients undergoing coronary stenting and angioplasty. Among patients undergoing coronary stenting, the cost-effectiveness ratio of the addition of abciximab was at or below the $50,000 per life year saved threshold in 66.0% of the simulations.

Published
2003

22. Acknowledging patient heterogeneity in economic evaluation : a systematic literature review

Author

Grutters, J.P.C., Sculpher, M., Briggs, A.H., Severens, J.L., Candel, M.J., Stahl, J.E., Ruysscher, D. de, Boer, A. de, Ramaekers, B.L., Joore, M.A., Grutters, J.P.C., Sculpher, M., Briggs, A.H., Severens, J.L., Candel, M.J., Stahl, J.E., Ruysscher, D. de, Boer, A. de, Ramaekers, B.L., and Joore, M.A.

Abstract

Item does not contain fulltext, BACKGROUND AND OBJECTIVE: Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic evaluations pay only limited attention to patient heterogeneity. The objective of the present paper is to provide a comprehensive overview of the current knowledge regarding patient heterogeneity within economic evaluation of healthcare programmes. METHODS: A systematic literature review was performed to identify methodological papers on the topic of patient heterogeneity in economic evaluation. Data were obtained using a keyword search of the PubMed database and manual searches. Handbooks were also included. Relevant data were extracted regarding potential sources of patient heterogeneity, in which of the input parameters of an economic evaluation these occur, methods to acknowledge patient heterogeneity and specific concerns associated with this acknowledgement. RESULTS: A total of 20 articles and five handbooks were included. The relevant sources of patient heterogeneity (demographics, preferences and clinical characteristics) and the input parameters where they occurred (baseline risk, treatment effect, health state utility and resource utilization) were combined in a framework. Methods were derived for the design, analysis and presentation phases of an economic evaluation. Concerns related mainly to the danger of false-positive results and equity issues. CONCLUSION: By systematically reviewing current knowledge regarding patient heterogeneity within economic evaluations of healthcare programmes, we provide guidance for future economic evaluations. Guidance is provided on which sources of patient heterogeneity to consider, how to acknowledge them in economic evaluation and potential concerns. The improved acknowledgement of patient heterogeneity i

Published
2013

23. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods

Author

O'Brien, B.J. and Briggs, A.H.

Subjects
RA, HJ
Abstract

Cost-effectiveness analysis is now an integral part of health technology assessment and addresses the question of whether a new treatment or other health care program offers good value for money. In this paper we introduce the basic framework for decision making with cost-effectiveness data and then review recent developments in statistical methods for analysis of uncertainty when cost-effectiveness estimates are based on observed data from a clinical trial. Although much research has focused on methods for calculating confidence intervals for cost-effectiveness ratios using bootstrapping or Fieller’s method, these calculations can be problematic with a ratio-based statistic where numerator and=or denominator can be zero. We advocate plotting the joint density of cost and effect differences, together with cumulative density plots known as cost-effectiveness acceptability curves (CEACs) to summarize the overall value-for-money of interventions. We also outline the net-benefit formulation of the cost-effectiveness problem and show that it has particular advantages over the standard incremental cost-effectiveness ratio formulation.

Published
2002

24. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

Author

Briggs, A.H., Goeree, R., Blackhouse, G., and O'Brien, B.J.

Subjects
Health Policy, RA, HG, RC
Abstract

When choosing between mutually exclusive treatment options, it is common to construct a cost-effectiveness frontier on the cost-effectiveness plane that represents efficient points from among the treatment choices. Treatment options internal to the frontier are considered inefficient and are excluded either by strict dominance or by appealing to the principle of extended dominance. However, when uncertainty is considered, options excluded under the baseline analysis may form part of the cost-effectiveness frontier. By adopting a Bayesian approach, where distributions for model parameters are specified, uncertainty in the decision concerning which treatment option should be implemented is addressed directly. The approach is illustrated using an example from a recently published cost-effectiveness analysis of different possible treatment strategies for gastroesophageal reflux disease.It is argued that probabilistic analyses should be encouraged because they have potential to quantify the strength of evidence in favor of particular treatment choices.

Published
2002

25. The death of cost-minimization analysis?

Author

Briggs, A.H. and O'Brien, B.J.

Subjects
RA, R1, HG
Abstract

Four different types of evaluation methods, cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-minimization analysis (CMA), are usually distinguished. In this note, we pronounce the (near) death of CMA by showing the rare circumstances under which CMA is an appropriate method of analysis. We argue that it is inappropriate for separate and sequential hypothesis tests on differences in effects and costs to determine whether incremental cost-effectiveness (or cost-utility) should be estimated. We further argue that the analytic focus should be on the estimation of the joint density of cost and effect differences, the quantification of uncertainty surrounding the incremental cost-effectiveness ratio and the presentation of such data as cost-effectiveness acceptability curves. Two examples from recently published CEA are employed to illustrate the issues. The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis.

Published
2001

26. Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty

Author

Briggs, A.H.

Subjects
Cost effectiveness, Computer science, Health Policy, Public Health, Environmental and Occupational Health, Probability theory and stochastic processes, HG, Probabilistic method, Sample size determination, Econometrics, Probability distribution, Probabilistic analysis of algorithms, Sensitivity analysis, RA, Decision model, Uncertainty analysis
Abstract

Oxford University, Oxford, UKThere was a time when a simple dichotomy charac-terized many health economic evaluations. On theone hand there were those economic appraisals thatwere conducted alongside clinical trials and whichcommonly employed statistical methods in so-calledstochastic evaluations. On the other, there was theuse of decision analytic modeling to synthesize datafrom secondary sources in order to estimate cost-effectiveness in a deterministic fashion. Now, how-ever, the distinctions are becoming ever moreblurred. The limitations of single trials as the solevehicle for economic appraisal is widely reported[1] and, in particular, the continued need for mod-eling to adapt trial-based analyses is well under-stood [2]. Furthermore, the use of probabilisticsensitivity analysis to represent uncertainty in mod-eling studies offers the opportunity to make statis-tical statements about the impact of parameteruncertainty for cost-effectiveness estimates fromdeterministic models.The trend toward a more statistical approach tohandling uncertainty in cost-effectiveness modelshas been picked up in the new guidance from theNational Institute for Clinical Excellence (NICE) inthe UK. NICE now advocates the use of a referencecase set of methods for those making submissions toits appraisal process [3]. Included within this refer-ence case is the recommendation to use probabilisticsensitivity analysis to represent parameter uncer-tainty. Journal editors and reviewers too are becom-ing more stringent in their requirements to see theuse of probabilistic methods to characterize param-eter uncertainty. In this issue of Value in Health,Oostenbrink and colleagues [4] present a probabil-istic model that typifies the approach to presentinguncertainty in such models. By characterizing theuncertainty in the input parameters of their modelas probability distributions, the authors are able topropagate that uncertainty through the model usingMonte Carlo simulation, thus generating a jointdistribution in the incremental costs and effectsthat represents the consequences of the input para-meter uncertainty. This is presented on the cost-effectiveness plane and can be summarized usingcost-effectiveness acceptability curves just as anystatistical analysis of costs and effects from a trial-based analysis.Probabilistic methods are not universallyaccepted, however. A common criticism levied atthe use of probabilistic analysis is that the choice ofdistribution is essentially arbitrary and generatesanother aspect of the analysis that must itself besubjected to sensitivity analysis. Although it is truethat the literature contains many examples of prob-abilistic sensitivity analyses that employ arbitrarydistributional forms, this is generally because theauthors have not thought carefully about the uncer-tainty in the parameter they are seeking to capture.Although there are clearly a large number of poten-tial distributions available in the software packagesused to produce cost-effectiveness models, it doesnot follow that they are all candidate distributionsfor every possible parameter. For any given param-eter in a decision model, the choice of distributionto characterize uncertainty in that parameter shouldbe chosen from a small number of candidate distri-butions which will depend on the data from whichthe parameter is estimated and the method of esti-mation. For example, a normal distribution isalways a candidate for any parameter based onexpected values because of the role of the CentralLimit Theorem, which essentially states that thesampling distribution of the mean will be normallydistributed whatever the underlying distribution ofthe data with sufficient sample size. Of course, mod-els will often be employed in situations where sam-ple sizes of data informing parameter estimationcannot be relied on to be sufficient and other distri-butional forms are required. Probability parame

Published
2005

30. Development of an economic model to assess the cost effectiveness of asthma management strategies.

Author

Price, M.J., Briggs, A.H., Price, Martin J, and Briggs, Andrew H

Subjects
*ASTHMA, *MEDICAL care costs, *STEROID drugs, *STEROIDS, *DRUG therapy for asthma, *ALBUTEROL, *ANTI-inflammatory agents, *BRONCHODILATOR agents, *COMPARATIVE studies, *COST effectiveness, *RESEARCH methodology, *MEDICAL cooperation, *PROBABILITY theory, *RESEARCH, *EVALUATION research, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *BLIND experiment, *QUALITY-adjusted life years, *STATISTICAL models, *ECONOMICS, *THERAPEUTICS
Abstract

Background and Objective: Asthma is a chronic-episodic disease characterised by acute, symptomatic episodes of varying severity. We developed a Markov model that can be used to estimate the cost effectiveness of alternative asthma treatments. Because of the costs they incur, asthma exacerbations ('attacks') requiring intervention by a healthcare professional were a central consideration in the development of the model.Methods: Treatment success was assessed as asthma control, a composite measure based on goals defined in world-wide asthma management guidelines and in terms of quality-adjusted life-years (QALYs). The data from which the transition probabilities were derived came from patients with asthma who received either salmeterol/fluticasone propionate combination (SFC) 50/100microg or fluticasone propionate (FP) 100microg, administered twice daily via an inhaler, in a 12-week, randomised, double-blind, clinical trial. Costs were estimated from resource profiles defined for each of the model states. A key aspect of the model was the use of probabilistic sensitivity analysis techniques to examine the uncertainty in the cost-effectiveness results. Distributions were fitted to transition probabilities and to cost input parameters and values were sampled at random from these distributions using a second order Monte Carlo simulation technique. This produced a distribution for incremental cost effectiveness that was employed to construct 95% uncertainty intervals and to construct cost effectiveness acceptability curves.Results: In this analysis, the model was run over a 12-week period using transition probabilities derived from the trial data. The results showed that treatment with SFC resulted in a higher proportion of successfully controlled weeks per patient than treatment with FP (66 vs 47%), and higher mean weekly direct asthma management costs (pound sterling 15.77 vs pound sterling 11.83; 2000 values). The average incremental cost per successfully controlled week with SFC was pound sterling 20.83. Probabilistic sensitivity analysis showed that the 95% uncertainty intervals for the incremental cost-effectiveness ratio was - pound sterling 64.94 to pound sterling 112.66. In approximately 25% of cases, SFC was dominant (more effective and less costly), but in the remaining cases, it was both more effective and more costly. It was shown that if decision makers are willing to pay approximately pound sterling 45 for an additional successfully controlled week, SFC will be the more cost-effective strategy in this patient population for 80% of the time.Conclusions: This is one of the first decision-analytic models of asthma to incorporate probabilistic sensitivity analysis techniques to explore uncertainty. The model's flexible yet standardised framework permits the cost effectiveness of alternative asthma management strategies in different healthcare settings to be established. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

31. Handling uncertainty in cost-effectiveness models.

Author

Briggs, A.H.

Subjects
*INFORMATION modeling, *CLINICAL trials, *UNCERTAINTY, *COST effectiveness, *PATIENTS, *VITAL statistics, *BAYESIAN analysis, *MONTE Carlo method, *PROBABILITY theory, *DECISION making, *STATISTICAL models
Abstract

The use of modelling in economic evaluation is widespread, and it most often involves synthesising data from a number of sources. However, even when economic evaluations are conducted alongside clinical trials, some form of modelling is usually essential. The aim of this article is to review the handling of uncertainty in the cost-effectiveness results that are generated by the use of decision-analytic-type modelling. The modelling process is split into a number of stages: (i) a set of methods to be employed in a study are defined, which should include a 'reference case' of agreed methods to enhance the comparability of results; (ii) the clinical and demographic characteristics of the patients the model relates to should be specified as carefully as in any experimental study; and (iii) the data requirements of the model should be estimated using the principles of Bayesian statistics, such that prior distributions are specified for unknown model parameters. Monte Carlo simulation can then be employed to sample from these prior distributions to obtain a distribution of the cost effectiveness of the intervention. Such probabilistic analyses are related to parameter uncertainty. In addition, modelling uncertainty is likely to add a further layer of uncertainty to the results of particular analyses. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

32. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of...

Author

Briggs, A.H. and Sculpher, M.J.

Subjects
*HELICOBACTER pylori infections, *INDIGESTION, *PEPTIC ulcer
Abstract

Assesses the cost effectiveness of screening for and eradication of Helicobacter pylori in patients with dyspepsia. Identification and treatment of peptic ulcer; Comparison with the cost effectiveness of conventional antisecretory treatment.

Published
1996
Full Text
View/download PDF

33. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting @b"2-agonists in a health maintenance organization

Author

Gagnon, Y.M., Levy, A.R., Spencer, M.D., Hurley, J.S., Frost, F.J., Mapel, D.W., and Briggs, A.H.

Abstract

Objectives: In light of recent results from observational studies showing prolonged survival in subjects taking long-acting @b"2-agonists (LABA) and/or inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD), we investigated their cost-effectiveness (CE). Methods: Costs and survival data were collected for a sample of members enrolled in a large Health Maintenance Organization in the United States. An observational study design was used to evaluate cumulative costs and health benefits of LABA, ICS, ICS+LABA, or comparison drugs. Survival was estimated using a parametric regression model. Costs were adjusted for censoring and prognostic factors. CE was evaluated over a time horizon of 36 months and the remaining lifetime of subjects. Results: Over 36 months, life expectancy and costs were: 2.4 years (95% confidence interval (CI): 2.3; 2.5) and $28,030 (CI: $23,400; $33,570) for not receiving ICS or LABA; 2.6 years (CI: 2.6; 2.7) and $35,170 (CI: $29,970; $40,620) for ICS alone; 2.6 years (CI: 2.5; 2.7) and $27,380 (CI: $21,780; $32,510) for LABA alone; and, 2.7 years (CI: 2.6; 2.8) and $33,780 (CI: $28,700; $39,440) for subjects treated with ICS+LABA. The lifetime analysis showed similar trends. Conclusions: There is an acute need to find effective, life-extending treatments for persons with COPD. ICS, LABA or their combination represent promising treatment options and are currently being tested in randomized trials. If the impact on survival seen in these trials compares to that seen in observational studies, LABA and the combination treatment are likely to be cost-effective in the United States.

Published
2005
Full Text
View/download PDF

34. Evaluation of health in pregnancy grants in Scotland: a protocol for a natural experiment

Author

Dundas, R., Ouédraogo, S., Bond, L., Briggs, A.H., Chalmers, J., Gray, R., Wood, R., and Leyland, A.H.

Abstract

Introduction: A substantial proportion of low birth weight is attributable to the mother's cultural and socioeconomic circumstances. Early childhood programmes have been widely developed to improve child outcomes. In the UK, the Health in Pregnancy (HiP) grant, a universal conditional cash transfer of £190, was introduced for women reaching the 25th week of pregnancy with a due date on/or after 6 April 2009 and subsequently withdrawn for women reaching the 25th week of pregnancy on/or after 1 January 2011. The current study focuses on the evaluation of the effectiveness and cost-effectiveness of the HiP grant.\ud \ud Methods and analysis: The population under study will be all singleton births in Scotland over the periods of January 2004 to March 2009 (preintervention), April 2009 to April 2011 (intervention) and May 2011 to December 2013 (postintervention). Data will be extracted from the Scottish maternity and neonatal database. The analysis period 2004–2013 should yield over 585 000 births. The primary outcome will be birth weight among singleton births. Other secondary outcomes will include gestation at booking, booking before 25 weeks; measures of size and stage; gestational age at delivery; weight-for-dates, term at birth; birth outcomes and maternal smoking. The main statistical method we will use is interrupted time series. Outcomes will be measured on individual births nested within mothers, with mothers themselves clustered within data zones. Multilevel regression models will be used to determine whether the outcomes changed during the period in which the HiP grants was in effect. Subgroup analyses will be conducted for those groups most likely to benefit from the payments.\ud \ud Ethics and dissemination: Approval for data collection, storage and release for research purpose has been given (6 May 2014, PAC38A/13) by the Privacy Advisory Committee. The results of this study will be disseminated through peer-reviewed publications in journals, national and international conferences.

35. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Author

Robles-Zurita, J., Boyd, K.A., Briggs, A.H., Iveson, T., Kerr, R.S., Saunders, M.P., Cassidy, J., Hollander, N.H., Tabernero, J., Segelov, E., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Pearson, S., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A.S., Hughes, R., Falk, S., Raouf, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, Tamas F., Weaver, A., Gollins, S., Wasan, H.S., Paul, J., Robles-Zurita, J., Boyd, K.A., Briggs, A.H., Iveson, T., Kerr, R.S., Saunders, M.P., Cassidy, J., Hollander, N.H., Tabernero, J., Segelov, E., Glimelius, B., Harkin, A., Allan, K., McQueen, J., Pearson, S., Waterston, A., Medley, L., Wilson, C., Ellis, R., Essapen, S., Dhadda, A.S., Hughes, R., Falk, S., Raouf, S., Rees, C., Olesen, R.K., Propper, D., Bridgewater, J., Azzabi, A., Farrugia, D., Webb, A., Cunningham, D., Hickish, Tamas F., Weaver, A., Gollins, S., Wasan, H.S., and Paul, J.

Abstract

BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken. RESULTS: The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant). CONCLUSIONS: Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care.

38. WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3 – Area 5)

Author

Bousquet, J., Farrell, J., Crooks, G., Hellings, P., Bel, E.H., Bewick, M., Chavannes, N.H., Correia de Sousa, J., Cruz, A.A., Haahtela, T., Joos, G., Khaltaev, N., Malva, J., Muraro, A., Nogues, M., Palkonen, S., Pedersen, S., Robalo-Cordeiro, C., Samolinski, B., Strandberg, T., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Bedbrook, A., Aberer, W., Adachi, M., Agusti, A., Akdis, C.A., Akdis, M., Ankri, J., Alonso, A., Annesi-Maesano, I., Ansotegui, I.J., Anto, J.M., Arnavielhe, S., Arshad, H., Bai, C., Baiardini, I., Bachert, C., Baigenzhin, A.K., Barbara, C., Bateman, E.D., Beghé, B., Ben Kheder, A., Bennoor, K.S., Benson, M., Bergmann, K.C., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Boner, A.L., Bonini, M., Bonini, S., Bosnic-Anticevitch, S., Boulet, L.P., Bourret, R., Bousquet, P.J., Braido, F., Briggs, A.H., Brightling, C.E., Brozek, J., Buhl, R., Burney, P.G., Bush, A., Caballero-Fonseca, F., Caimmi, D., Calderon, M.A., Calverley, P.M., Camargos, P.A.M., Canonica, G.W., Camuzat, T., Carlsen, K.H., Carr, W., Carriazo, A., Casale, T., Cepeda Sarabia, A.M., Chatzi, L., Chen, Y.Z., Chiron, R., Chkhartishvili, E., Chuchalin, A.G., Chung, K.F., Ciprandi, G., Cirule, I., Cox, L., Costa, D.J., Custovic, A., Dahl, R., Dahlen, S.E., Darsow, U., De Carlo, G., De Blay, F., Dedeu, T., Deleanu, D., De Manuel Keenoy, E., Demoly, P., Denburg, J.A., Devillier, P., Didier, A., Dinh-Xuan, A.T., Djukanovic, R., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S.R., Dykewicz, M.S., El-Gamal, Y., Emuzyte, R., Fabbri, L.M., Fletcher, M., Fiocchi, A., Fink Wagner, A., Fonseca, J., Fokkens, W.J., Forastiere, F., Frith, P., Gaga, M., Gamkrelidze, A., Garces, J., Garcia-Aymerich, J., Gemicioğlu, B., Gereda, J.E., González Diaz, S., Gotua, M., Grisle, I., Grouse, L., Gutter, Z., Guzmán, M.A., Heaney, L.G., Hellquist-Dahl, B., Henderson, D., Hendry, A., Heinrich, J., Heve, D., Horak, F., Hourihane, J.O’B., Howarth, P., Humbert, M., Hyland, M.E., Illario, M., Ivancevich, J.C., Jardim, J.R., Jares, E.J., Jeandel, C., Jenkins, C., Johnston, S.L., Jonquet, O., Julge, K., Jung, K.S., Just, J., Kaidashev, I., Kaitov, M.R., Kalayci, O., Kalyoncu, A.F., Keil, T., Keith, P.K., Klimek, L., Koffi N’Goran, B., Kolek, V., Koppelman, G.H., Kowalski, M.L., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Lau, S., Larenas-Linnemann, D., Laune, D., Le, L.T.T., Lieberman, P., Lipworth, B., Li, J., Lodrup Carlsen, K., Louis, R., MacNee, W., Magard, Y., Magnan, A., Mahboub, B., Mair, A., Majer, I., Makela, M.J., Manning, P., Mara, S., Marshall, G.D., Masjedi, M.R., Matignon, P., Maurer, M., Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E.O., Menzies-Gow, A., Merk, H., Michel, J.P., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda Y. Mohammad, G., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Morgan, M., Mösges, R., Mullol, J., Nafti, S., Namazova-Baranova, L., Naclerio, R., Neou, A., Neffen, H., Nekam, K., Niggemann, B., Ninot, G., Nyembue, T.D., O’Hehir, R.E., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Panzner, P., Papadopoulos, N., Papi, A., Park, H.S., Passalacqua, G., Pavord, I., Pawankar, R., Pengelly, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Poethig, D., Pohl, W., Popov, T.A., Portejoie, F., Potter, P., Postma, D., Price, D., Rabe, K.F., Raciborski, F., Radier Pontal, F., Repka-Ramirez, S., Reitamo, S., Rennard, S., Rodenas, F., Roberts, J., Roca, J., Rodriguez Mañas, L., Rolland, C., Roman Rodriguez, M., Romano, A., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Ryan, D., Sanchez-Borges, M., Scadding, G.K., Schunemann, H.J., Serrano, E., Schmid-Grendelmeier, P., Schulz, H., Sheikh, A., Shields, M., Siafakas, N., Sibille, Y., Similowski, T., Simons, F.E.R., Sisul, J.C., Skrindo, I., Smit, H.A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sterk, P.J., Sunyer, J., Thijs, C., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A.L., Valia, E., Valovirta, E., Van Ganse, E., van Hage, M., Vandenplas, O., Vasankari, T., Vellas, B., Vestbo, J., Vezzani, G., Vichyanond, P., Viegi, G., Vogelmeier, C., Vontetsianos, T., Wagenmann, M., Wallaert, B., Walker, S., Wang, D.Y., Wahn, U., Wickman, M., Williams, D.M., Williams, S., Wright, J., Yawn, B.P., Yiallouros, P.K., Yusuf, O.M., Zaidi, A., Zar, H.J., Zernotti, M.E., Zhang, L., Zhong, N., Zidarn, M., and Mercier, J.

Full Text
View/download PDF

39. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

Author

Hellings, P. W., Fokkens, W. J., Bachert, C., Akdis, C. A., Bieber, T., Agache, I., Bernal-Sprekelsen, M., Canonica, G. W., Gevaert, P., Joos, G., Lund, V. J., Muraro, A., Onerci, M., Zuberbier, T., Pugin, B., Seys, S. F., Bousquet, Jean, ARIA and EPOS working groups, Akdis, M., Alobid, I., Ankri, J., Annesi-Maesano, I., Ansotegui, I. J., Anto, Josep M., Arnavielhe, S., Arshad, S. H., Asarnoj, A., Avolio, F., Baiardini, I., Barbagallo, Carlo M., Barbara, Cristina, Baroody, F., Bateman, E. D., Bedbrook, Anna, Beghé, B., Bel, E. H., Bennoor, K. S., Benson, M., Bergmann, K. C., Bewick, M., Białoszewski, A. Z., Bindslev-Jensen, C., Bjermer, L., Blain, Hubert, Blasi, F., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevitch, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, Rodolphe, Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J. L., Bucca, C., Buhl, R., Bunu, C., Burte, E., Bush, A., Caballero-Fonseca, F., Caimmi, D. P., Calderon, M. A., Camargos, P. A. M., Camuzat, Thierry, Cardona, V., Carlsen, K. H., Carr, W., Carreiro-Martins, P., Carriazo, A. M., Casale, T. B., A.M, Cepeda Sarabia, Cervin, A., Cesari, M., Chatzi, L., Chavannes, Niels H., Chiron, R., Pérez, T. Chivato, Chkhartishvili, E., Chuchalin, Alexander G., Chung, K. F., Ciprandi, G., Cohen, N., Diaz, S. Conzález, Cox, L., Crooks, George, Cruz, A. A., Custovic, Adnan, Dahl, R., Dahlen, S. E., Darsow, U., Carlo, G. De, Keenoy, E. De Manuel, Sousa, J. Correia de, Vries, Elisabeth G. E. de, Dedeu, Antoni, Deleanu, D., Demoly, Pascal, Denburg, J. A., Devillier, P., Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H. B., Douglas, R., Dray, G., Toit, G. Du, Dubakiene, R., Durham, S. R., Dykewicz, M. S., Eklund, P., El-Gamal, Y., Ellers, E., Emuzyte, R., Farrell, J., Fink-Wagner, A., Fiocchi, A., Fletcher, M., Fonseca, J. A., Forastiere, F., Gaga, M., Gamkrelidze, A., Gemicioǧlu, B., Georgalas, C., Gereda, J. E., Goossens, H., Grisle, I., Guldemond, N. A., Gutter, Z., Guzmán, M. A., Haahtela, T., Harvey, R., Heinrich, J., Hellquist-Dahl, B., Hopkins, C., Horak, F., Hourihane, J. O. B., Humbert, M., Hyland, M. E., Iaccarino, G., Illario, M., Jares, E. J., Jeandel, Claude, Johnston, S. L., Jonquet, Olivier, Jung, K. S., Just, J., Jutel, M., Kaidashev, I. P., Kalayci, O., Kalogjera, L., Kalyoncu, A. F., Kardas, P., Keil, T., Keith, P. K., Kerkhof, M., Kern, B., Kerstjens, H. A. M., Khaitov, M. R., Khaltaev, N., Klimek, L., Kogevinas, M., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Larenas-Linnemann, D., Lau, S., Laune, D., Le, Tuyen D., Li, J., Lieberman, P., Lipworth, B. J., Carlsen, K. C. Lodrup, Louis, R., Lupinek, C., MacNee, W., Magard, Y., Magnan, A., Mahboub, B., Maier, D., Majer, I., Malva, J., Manning, P. J., Marshall, G. D., Masjedi, M. R., Mathieu-Dupas, E., Maurer, M., Mavale-Manuel, S., Melén, E., Gomes, Elisabete Melo, Meltzer, E. O., Mercier, Jacques, Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mohammad, Y., Momas, I., Almeida, M. Morais, Mosges, R., Mullol, J., Murray, R., Naclerio, R. N., Nadif, R., Namazova-Baranova, L., Neffen, H., Nekam, K., Nieto, A., Niggemann, B., Nogueira-Silva, L., Nogues, M., Nyembue, T. D., O'Hehir, R. E., Ohta, K., Okamoto, Y., Okubo, K., Olive-Elias, M., Ouedraogo, S., Paggiaro, P. L., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Papi, A., Park, H. S., Passalacqua, G., Pawankar, R., Pedersen, S., Pereira, A. M., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D. S., Potter, P., Poulsen, L. K., Price, D., Rabe, K. F., Raciborski, F., Riechelmann, H., Robalo-Cordeiro, C., Roberts, G., Rodenas, F., Rodriguez-Mañas, L., Rolland, C., Rodriguez, M. Roman, Romano, A., Rosado-Pinto, J., Rosario, N. A., Rottem, M., Ryan, D., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schlosser, R., Schmid-Grendelmeier, P., Schunemann, H. J., Scichilone, N., Senior, B., Serrano, E., Sheikh, A., Shields, K. M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Smit, H. A., Sole, D., Sooronbaev, T., Spranger, O., Stellato, C., Stelmach, R., Sterk, P. J., Strandberg, T., Sunyer, Jordi, Thijs, C., Thomas, M., Todo-Bom, A., Tomazic, P. V., Toskala, E., Triggiani, M., Valenta, R., Valero, A. L., Valiulis, A., Valovirta, E., Eerd, M. van, Ganse, E. van, Hage, M. van, Wick, R. G. van, Vandenplas, O., Varona, L. L., Vazankari, T., Vellas, B., Ventura, M. T., Vezzani, G., Viegi, Giovanni, Voegels, R., Vontetsianos, T., Wagenmann, M., Wahn, U., Walker, S., Wang, D. Y., Wang, Ya Xing, Werfel, T., Whalley, B., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wormald, P. J., Wright, J., Yawn, B. P., Yiallouros, Panayiotis K., Yorgancioglu, A., Young, I., Yusuf, O. M., Zaidi, A., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., Adult Psychiatry, Ear, Nose and Throat, AII - Inflammatory diseases, AII - Amsterdam institute for Infection and Immunity, Pulmonology, Other departments, Hellings, P. W., Fokkens, W. J., Bachert, C., Akdis, C. A., Bieber, T., Agache, I., Bernal-Sprekelsen, M., Canonica, G. W., Gevaert, P., Joos, G., Lund, V., Muraro, A., Onerci, M., Zuberbier, T., Pugin, B., Seys, S. F., Bousquet, J., Aberer, W., Akdis, M., Alobid, I., Ankri, J., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielhe, S., Arshad, H., Asarnoj, A., Avolio, F., Baiardini, I., Barbagallo, M., Barbara, C., Baroody, F., Bateman, E. D., Bedbrook, A., Beghe, B., Bel, E. H., Bennoor, K. S., Benson, M., Bergmann, K. C., Bewick, M., Bialoszewski, A. Z., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevich, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Bunu, C., Burte, E., Bush, A., Caballero-Fonseca, F., Caimmi, D. P., Calderon, M. A., Camargos, P. A., Camuzat, T., Cardona, V., Carlsen, K. H., Carr, W., Carreiro-Martins, P., Carriazo, A. M., Casale, T., Cepeda Sarabia, A. M., Cervin, A., Cesari, M., Chatzi, L., Chavannes, N. H., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciprandi, G., Cohen, N., Conzalez Diaz, S., Cox, L., Crooks, G., Cruz, A. A., Custovic, A., Dahl, R., Dahlen, S. E., Darsow, U., De Carlo, G., De Manuel Keenoy, E., de Sousa, J. C., De Vries, G., Dedeu, T., Deleanu, D., Demoly, P., Denburg, J. A., Devillier, P., Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H., Douglas, R., Dray, G., Du Toit, G., Dubakiene, R., Durham, S. R., Dykewicz, M. S., Eklund, P., El-Gamal, Y., Ellers, E., Emuzyte, R., Farrell, J., Fink Wagner, A., Fiocchi, A., Fletcher, M., Fonseca, J., Forastiere, F., Gaga, M., Gamkrelidze, A., Gemicioglu, B., Georgalas, C., Gereda, J. E., Goossens, H., Grisle, I., Guldemond, N. A., Gutter, Z., Guzman, M. A., Haahtela, T., Harvey, R., Heinrich, J., Hellquist-Dahl, B., Hopkins, C., Horak, F., Hourihane, J. O., Humbert, M., Hyland, M., Iaccarino, G., Illario, M., Jares, E. J., Jeandel, C., Johnston, S. L., Jonquet, O., Jung, K. S., Just, J., Jutel, M., Kaidashev, I. P., Kalayci, O., Kalogjera, L., Kalyoncu, A. F., Kardas, P., Keil, T., Keith, P. K., Kerkhof, M., Kern, B., Kerstjens, H. A., Khaitov, M., Khaltaev, N., Klimek, L., Kogevinas, M., Kolek, V., Koppelman, G. H., Kowalski, M., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kvedariene, V., Lambrecht, B., Larenas-Linnemann, D., Lau, S., Laune, D., Le, L. T., Li, J., Lieberman, P., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lund, V. J., Lupinek, C., Macnee, W., Magar, Y., Magnan, A., Mahboub, B., Maier, D., Majer, I., Malva, J., Manning, P., Marshall, G. D., Masjedi, M. R., Mathieu-Dupas, E., Maurer, M., Mavale-Manuel, S., Melen, E., Melo-Gomes, E., Meltzer, E. O., Mercier, J., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mohammad, Y., Momas, I., Morais-Almeida, M., Mosges, R., Mullol, J., Murray, R., Naclerio, R., Nadif, R., Namazova-Baranova, L., Neffen, H., Nekam, K., Nieto, A., Nogues, M., Nyembue, T. D., O'Hehir, R. E., Ohta, K., Okamoto, Y., Okubo, K., Olive-Elias, M., Ouedraogo, S., Paggiaro, P., Pali-Scholl, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Papi, A., Park, H. S., Passalacqua, G., Niggemann, B., Nogueira-Silva, L., Pereira, A. M., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D., Potter, P., Poulsen, L. K., Price, D., Rabe, K. F., Raciborski, F., Riechelmann, H., Robalo-Cordeiro, C., Roberts, G., Rodenas, F., Rodriguez-Manas, L., Rolland, C., Roman Rodriguez, M., Romano, A., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schlosser, R., Schmid-Grendelmeier, P., Schunemann, H. J., Scichilone, N., Senior, B., Serrano, E., Sheikh, A., Shields, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Smit, H. A., Sole, D., Sooronbaev, T., Spranger, O., Stellato, C., Stelmach, R., Sterk, P. J., Strandberg, T., Sunyer, J., Thijs, C., Thomas, M., Todo-Bom, A., Tomazic, P. V., Toskala, E., Triggiani, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hage, M., van Wick, R. G., Vandenplas, O., Varona, L. L., Vazankari, T., Vellas, B., Ventura, M. T., Vezzani, G., Viegi, G., Voegels, R., Vontetsianos, T., Wagenmann, M., Wahn, U., Walker, S., Wang, D. Y., Wang, Y., Werfel, T., Whalley, B., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wormald, P. J., Wright, J., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Young, I., Yusuf, O. M., Zaidi, A., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., Asthma UK, Department of Dermatology, Allergology and Venereology, Clinicum, HUS Inflammation Center, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Custovic, Adnan [0000-0001-5218-7071], Hellings, P.W., Fokkens, W.J., Akdis, C.A., Canonica, G.W., Seys, S.F., Ansotegui, I.J., Anto, J.M., Bateman, E.D., Beghé, B., Bel, E.H., Bennoor, K.S., Bergmann, K.C., Bialoszewski, A.Z., Boner, A.L., Boulet, L.P., Bousquet, P.J., Briggs, A.H., Brightling, C.E., Caimmi, D.P., Calderon, M.A., Camargos, P.A., Carlsen, K.H., Carriazo, A.M., Cepeda Sarabia, A.M., Chavannes, N.H., Chuchalin, A.G., Chung, K.F., Conzález Diaz, S., Cruz, A.A., Dahlen, S.E., de Sousa, J.C., Denburg, J.A., Dinh-Xuan, A.T., Durham, S.R., Dykewicz, M.S., Gemicioğlu, B., Gereda, J.E., Guldemond, N.A., Guzmán, M.A., Hourihane, J.O., Jares, E.J., Johnston, S.L., Jung, K.S., Kaidashev, I., Kalyoncu, A.F., Keith, P.K., Kerstjens, H.A., Koppelman, G.H., Kowalski, M.L., Le, L.T., Lodrup Carlsen, K.C., Lund, V.J., MacNee, W., Marshall, G.D., Masjedi, M.R., Melén, E., Meltzer, E.O., Mösges, R., Nyembue, T.D., O'Hehir, R.E., Pali-Schöll, I., Papadopoulos, N.G., Park, H.S., Pawankar, R., Pedersen, S., Pereira, A.M., Popov, T.A., Poulsen, L.K., Rabe, K.F., Rodriguez-Mañas, L., Scadding, G.K., Schunemann, H.J., Simons, F.E.R., Sisul, J.C., Smit, H.A., Solé, D., Sterk, P.J., Tomazic, P.V., van Wick, R.G., Varona, L.L., Ventura, M.T., Wang, D.Y., Williams, D.M., Wormald, P.J., Yawn, B.P., Yiallouros, P.K., Yusuf, O.M., Zar, H.J., and Zernotti, M.E.

Subjects
allergic rhinitis, integrated care pathway, precision medicine, rhinosinusitis, Allergy, Rhinosinusitis, Disease, Allergic rhinitis, 0302 clinical medicine, QUALITY-OF-LIFE, Medicine, Immunology and Allergy, 030223 otorhinolaryngology, Sinusitis, NASAL POLYPOSIS, Rhinitis, Precision medicine, 3. Good health, Algorithm, REAL-LIFE, IMPACT OUTCOMES, ARIA and EPOS working groups, 1107 Immunology, DISEASES, GA(2)LEN, Disease Progression, allergic rhiniti, Life Sciences & Biomedicine, ENDOSCOPIC SINUS SURGERY, Algorithms, Human, Integrated care pathway, Adult, Chronic Disease, Humans, Precision Medicine, Rhinitis, Allergic, Young Adult, Immunology, medicine.medical_specialty, rhinosinusiti, PHENOTYPES, VALIDATION, 03 medical and health sciences, Therapeutic approach, Allergic, Patient satisfaction, Quality of life (healthcare), Patient participation, IMMUNOTHERAPY, Intensive care medicine, Asthma, Science & Technology, business.industry, medicine.disease, Sinusiti, SEVERITY, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Physical therapy, ASTHMA, business
Abstract

Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document was to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second-level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its implementation and the high cost of molecular diagnosis and biological treatment. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. 72 9 1297 1305

Published
2017

40. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

Author

Bousquet, J., Schünemann, H.J., Hellings, P.W., Arnavielhe, S., Bachert, C., Bedbrook, A., Bergmann, K.C., Bosnic-Anticevich, S., Brozek, J., Calderon, M., Canonica, G.W., Casale, T.B., Chavannes, N.H., Cox, L., Chrystyn, H., Cruz, A.A., Dahl, R., De Carlo, G., Demoly, P., Devillier, P., Dray, G., Fletcher, M., Fokkens, W.J., Fonseca, J., Gonzalez-Diaz, S.N., Grouse, L., Keil, T., Kuna, P., Larenas-Linnemann, D., Lodrup Carlsen, K.C., Meltzer, E.O., Mullol, J., Muraro, A., Naclerio, R.N., Palkonen, S., Papadopoulos, N.G., Passalacqua, G., Price, D., Ryan, D., Samolinski, B., Scadding, G.K., Sheikh, A., Spertini, F., Valiulis, A., Valovirta, E., Walker, S., Wickman, M., Yorgancioglu, A., Haahtela, T., Zuberbier, T., MASK study group, Aberer, W., Adachi, M., Agache, I., Akdis, C., Akdis, M., Annesi-Maesano, I., Ansotegui, I.J., Anto, J.M., Arshad, S.H., Baiardini, I., Baigenzhin, A.K., Barbara, C., Bateman, E.D., Beghé, B., Bel, E.H., Ben Kheder, A., Bennoor, K.S., Benson, M., Bernstein, D., Michael, B., Thomas, B., Bindslev-Jensen, C., Bjermer, L., Blain, H., Boner, A., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L.P., Bourret, R.A., Bousquet, P.J., Braido, F., Briggs, A.H., Brightling, C.E., Buhl, R., Burney, P., Bush, A., Caballero-Fonseca, F., Caimmi, D.P., Camargos, P., Camuzat, T., Carlsen, K.H., Carr, W., Casale, T.B., Sarabia, A.C., Chatzi, L., Chen, Y., Chiron, R., Chkhartishvili, E., Chuchalin, A., Ciprandi, G., Cirule, I., Correia de Sousa, J., Costa, D., Crooks, G., Custovic, A., Dahlen, S.E., Darsow, U., De Blay, F., De Manuel Keenoy, E., Dedeu, T., Deleanu, D., Denburg, J., Didier, A., Dinh-Xuan, A.T., Dokic, D., Douagui, H.B., Dubakiene, R., Durham, S., Dykewicz, M., El-Gamal, Y., Emuzyte, R., Fink-Wagner, A., Fiocchi, A., Forastiere, F., Gamkrelidze, A., Gemicioğlu, B., Gereda, J.E., Gerth van Wijk, R., Gotua, M., Grisle, I., Guzmán, M.A., Haahtela, T., Heinrich, J., Hellquist-Dahl, B., Horak, F., Howarth, P.H., Humbert, M., Hyland, M., Ivancevich, J.C., Jares, E.J., Johnston, S.L., Jonquet, O., Joos, G., Jung, K.S., Just, J., Jutel, M., Kaidashev, I.P., Khaitov, M., Kalayci, O., Kalyoncu, F., Keith, P., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., N'Goran, B.K., Kolek, V., Koppelman, G.H., Kowalski, M., Kull, I., Kvedariene, V., Lambrecht, B., Lau, S., Laune, D., Le Thi Tuyet, L., Li, J., Lieberman, P., Lipworth, B.J., Renaud, L., Magard, Y., Magnan, A., Mahboub, B., Majer, I., Makela, M., Manning, P.J., Masjedi, M.R., Maurer, M., Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Mercier, J., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Mohammad, Y., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Mösges, R., Nadif, R., Namazova-Baranova, L., Neffen, H., Nekam, K., Neou, A., Niggemann, B., Nyembue, D., O'Hehir, R., Ohta, K., Okamoto, Y., Okubo, K., Ouedraogo, S., Paggiaro, P.L., Pali-Schöll, I., Palmer, S., Panzner, P., Papi, A., Park, H.S., Pavord, I., Pawankar, R., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T., Postma, D.S., Potter, P., Poulsen, L.K., Rabe, K.F., Raciborski, F., Pontal, F.R., Reitamo, S., Repka-Ramirez, M.S., Robalo-Cordeiro, C., Roberts, G., Rodenas, F., Rolland, C., Rodriguez, M.R., Romano, A., Rosado-Pinto, J., Rosario, N.A., Rosenwasser, L., Rottem, M., Sanchez-Borges, M., Sastre-Dominguez, J., Schmid-Grendelmeier, P., Serrano, E., Simons, F.E., Sisul, J.C., Skrindo, I., Smit, H.A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Strandberg, T., Sunyer, J., Thijs, C., Todo-Bom, A.M., Triggiani, M., Valenta, R., Valero, A.L., van Hage, M., Vandenplas, O., Vezzani, G., Vichyanond, P., Viegi, G., Wagenmann, M., Wahn, U., De Yun, W., Williams, D., Wright, J., Yawn, B.P., Yiallouros, P., Yusuf, O.M., Zar, H.J., Zernotti, M., Zhang, L., Zhong, N., and Zidarn, M.

Subjects
Adolescent, Adult, Age Factors, Algorithms, Clinical Decision-Making, Conjunctivitis, Allergic/diagnosis, Conjunctivitis, Allergic/prevention & control, Conjunctivitis, Allergic/therapy, Disease Management, Humans, Patient Satisfaction, Rhinitis, Allergic/diagnosis, Rhinitis, Allergic/prevention & control, Rhinitis, Allergic/therapy
Abstract

The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials.

Published
2016

41. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

Author

Bousquet, Jean, Hellings, P. W., Agache, I., Bedbrook, Anna, Bachert, C., Bergmann, K. C., Bewick, M., Bindslev-Jensen, C., Bosnic-Anticevitch, S., Bucca, C., Caimmi, D. P., Camargos, P. A. M., Canonica, G. W., Casale, T. B., Chavannes, Niels H., Cruz, A. A., Carlo, G. De, Dahl, R., Demoly, Pascal, Devillier, P., Fonseca, J. A., Fokkens, W. J., Guldemond, N. A., Haahtela, T., Illario, M., Just, J., Keil, T., Klimek, L., Kuna, P., Larenas-Linnemann, D., Almeida, M. Morais, Mullol, J., Murray, R., Naclerio, R. N., O'Hehir, R. E., Papadopoulos, N. G., Pawankar, R., Potter, P., Ryan, D., Samolinski, B., Schunemann, H. J., Sheikh, A., Simons, F. E. R., Stellato, C., Todo-Bom, A., Tomazic, P. V., Valiulis, A., Valovirta, E., Ventura, M. T., Wickman, M., Young, I., Yorgancioglu, A., Zuberbier, T., Aberer, W., Akdis, C. A., Akdis, M., Annesi-Maesano, I., Ankri, J., Ansotegui, I. J., Anto, Josep M., Arnavielhe, S., Asarnoj, A., Arshad, S. H., Avolio, F., Baiardini, I., Barbara, Cristina, Barbagallo, Carlo M., Bateman, E. D., Beghé, B., Bel, E. H., Bennoor, K. S., Benson, M., Białoszewski, A. Z., Bieber, T., Bjermer, L., Blain, Hubert, Blasi, F., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, Rodolphe, Braido, F., Briggs, A. H., Brightling, C. E., Brozek, J. L., Buhl, R., Bunu, C., Burte, E., Bush, A., Caballero-Fonseca, F., Calderon, M. A., Camuzat, Thierry, Cardona, V., Carreiro-Martins, P., Carriazo, A. M., Carlsen, K. H., Carr, W., A.M, Cepeda Sarabia, Cesari, M., Chatzi, L., Chiron, R., Pérez, T. Chivato, Chkhartishvili, E., Chuchalin, Alexander G., Chung, K. F., Ciprandi, G., Sousa, J. Correia de, Cox, L., Crooks, George, Custovic, Adnan, Dahlen, S. E., Darsow, U., Dedeu, Antoni, Deleanu, D., Denburg, J. A., Vries, Elisabeth G. E. de, Didier, A., Dinh-Xuan, A. T., Dokic, D., Douagui, H. B., Dray, G., Dubakiene, R., Durham, S. R., Toit, G. Du, Dykewicz, M. S., Eklund, P., El-Gamal, Y., Ellers, E., Emuzyte, R., Farrell, J., Fink-Wagner, A., Fiocchi, A., Fletcher, M., Forastiere, F., Gaga, M., Gamkrelidze, A., Gemicioǧlu, B., Gereda, J. E., Wick, R. G. van, Diaz, S. González, Grisle, I., Grouse, L., Gutter, Z., Guzmán, M. A., Hellquist-Dahl, B., Heinrich, J., Horak, F., Hourihane, J. O. B., Humbert, M., Hyland, M. E., Iaccarino, G., Jares, E. J., Jeandel, Claude, Johnston, S. L., Joos, G., Jonquet, Olivier, Jung, K. S., Jutel, M., Kaidashev, I. P., Khaitov, M. R., Kalayci, O., Kalyoncu, A. F., Kardas, P., Keith, P. K., Kerkhof, M., Kerstjens, H. A. M., Khaltaev, N., Kogevinas, M., Kolek, V., Koppelman, G. H., Kowalski, M. L., Kuitunen, M., Kull, I., Kvedariene, V., Lambrecht, B., Lau, S., Laune, D., Le, Tuyen D., Lieberman, P., Lipworth, B. J., Li, J., Carlsen, K. C. Lodrup, Louis, R., Lupinek, C., MacNee, W., Magard, Y., Magnan, A., Mahboub, B., Maier, D., Majer, I., Malva, J., Manning, P. J., Keenoy, E. De Manuel, Marshall, G. D., Masjedi, M. R., Mathieu-Dupas, E., Maurer, M., Mavale-Manuel, S., Melén, E., Gomes, Elisabete Melo, Meltzer, E. O., Mercier, Jacques, Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mohammad, Y., Momas, I., Mosges, R., Muraro, A., Namazova-Baranova, L., Nadif, R., Neffen, H., Nekam, K., Nieto, A., Niggemann, B., Nogueira-Silva, L., Nogues, M., Nyembue, T. D., Ohta, K., Okamoto, Y., Okubo, K., Olive-Elias, M., Ouedraogo, S., Paggiaro, P. L., Pali-Schöll, I., Palkonen, S., Panzner, P., Papi, A., Park, H. S., Passalacqua, G., Pedersen, S., Pereira, A. M., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Postma, D. S., Poulsen, L. K., Price, D., Rabe, K. F., Raciborski, F., Roberts, G., Robalo-Cordeiro, C., Rodenas, F., Rodriguez-Mañas, L., Rolland, C., Rodriguez, M. Roman, Romano, A., Rosado-Pinto, J., Rosario, N. A., Rottem, M., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Scichilone, N., Schmid-Grendelmeier, P., Serrano, E., Shields, K. M., Siroux, V., Sisul, J. C., Skrindo, I., Smit, H. A., Sole, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sterk, P. J., Strandberg, T., Sunyer, Jordi, Thijs, C., Triggiani, M., Valenta, R., Valero, A. L., Eerd, M. Van, Ganse, E. Van, Hage, M. van, Vandenplas, O., Varona, L. L., Vellas, B., Vezzani, G., Vazankari, T., Viegi, Giovanni, Vontetsianos, T., Wagenmann, M., Walker, S., Wang, D. Y., Wahn, U., Werfel, T., Whalley, B., Williams, D. M., Williams, S., Wilson, N., Wright, J., Yawn, B. P., Yiallouros, Panayiotis K., Yusuf, O. M., Zaidi, A., Zar, H. J., Zernotti, M. E., Zhang, L., Zhong, N., Zidarn, M., Repositório da Universidade de Lisboa, Bousquet, J., Hellings, P.W., Agache, I., Bedbrook, A., Bachert, C., Bergmann, K.C., Bewick, M., Bindslev-Jensen, C., Bosnic-Anticevitch, S., Bucca, C., Caimmi, D.P., Camargos, P.A.M., Canonica, G.W., Casale, T., Chavannes, N.H., Cruz, A.A., De Carlo, G., Dahl, R., Demoly, P., Devillier, P., Fonseca, J., Fokkens, W.J., Guldemond, N.A., Haahtela, T., Illario, M., Just, J., Keil, T., Klimek, L., Kuna, P., Larenas-Linnemann, D., Morais-Almeida, M., Mullol, J., Murray, R., Naclerio, R., O'Hehir, R.E., Papadopoulos, N.G., Pawankar, R., Potter, P., Ryan, D., Samolinski, B., Schunemann, H.J., Sheikh, A., Simons, F.E.R., Stellato, C., Todo-Bom, A., Tomazic, P.V., Valiulis, A., Valovirta, E., Ventura, M.T., Wickman, M., Young, I., Yorgancioglu, A., Zuberbier, T., Aberer, W., Akdis, C.A., Akdis, M., Annesi-Maesano, I., Ankri, J., Ansotegui, I.J., Anto, J.M., Arnavielhe, S., Asarnoj, A., Arshad, H., Avolio, F., Baiardini, I., Barbara, C., Barbagallo, M., Bateman, E.D., Beghé, B., Bel, E.H., Bennoor, K.S., Benson, M., Białoszewski, A.Z., Bieber, T., Bjermer, L., Blain, H., Blasi, F., Boner, A.L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L.P., Bourret, R., Bousquet, P.J., Braido, F., Briggs, A.H., Brightling, C.E., Brozek, J., Buhl, R., Bunu, C., Burte, E., Bush, A., Caballero-Fonseca, F., Calderon, M.A., Camuzat, T., Cardona, V., Carreiro-Martins, P., Carriazo, A.M., Carlsen, K.H., Carr, W., Cepeda Sarabia, A.M., Cesari, M., Chatzi, L., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A.G., Chung, K.F., Ciprandi, G., De Sousa, J. Correia, Cox, L., Crooks, G., Custovic, A., Dahlen, S.E., Darsow, U., Dedeu, T., Deleanu, D., Denburg, J.A., De Vries, G., Didier, A., Dinh-Xuan, A.T., Dokic, D., Douagui, H., Dray, G., Dubakiene, R., Durham, S.R., Du Toit, G., Dykewicz, M.S., Eklund, P., El-Gamal, Y., Ellers, E., Emuzyte, R., Farrell, J., Fink Wagner, A., Fiocchi, A., Fletcher, M., Forastiere, F., Gaga, M., Gamkrelidze, A., Gemicioǧlu, B., Gereda, J.E., Van Wick, R. Gerth, González Diaz, S., Grisle, I., Grouse, L., Gutter, Z., Guzmán, M.A., Hellquist-Dahl, B., Heinrich, J., Horak, F., Hourihane, J.O.B., Humbert, M., Hyland, M., Iaccarino, G., Jares, E.J., Jeandel, C., Johnston, S.L., Joos, G., Jonquet, O., Jung, K.S., Jutel, M., Kaidashev, I., Khaitov, M., Kalayci, O., Kalyoncu, A.F., Kardas, P., Keith, P.K., Kerkhof, M., Kerstjens, H.A.M., Khaltaev, N., Kogevinas, M., Kolek, V., Koppelman, G.H., Kowalski, M.L., Kuitunen, M., Kull, I., Kvedariene, V., Lambrecht, B., Lau, S., Laune, D., Le, L.T.T., Lieberman, P., Lipworth, B., Li, J., Lodrup Carlsen, K.C., Louis, R., Lupinek, C., MacNee, W., Magar, Y., Magnan, A., Mahboub, B., Maier, D., Majer, I., Malva, J., Manning, P., De Manuel Keenoy, E., Marshall, G.D., Masjedi, M.R., Mathieu-Dupas, E., Maurer, M., Mavale-Manuel, S., Melén, E., Melo-Gomes, E., Meltzer, E.O., Mercier, J., Merk, H., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mohammad, Y., Momas, I., Mösges, R., Muraro, A., Namazova-Baranova, L., Nadif, R., Neffen, H., Nekam, K., Nieto, A., Niggemann, B., Nogueira-Silva, L., Nogues, M., Nyembue, T.D., Ohta, K., Okamoto, Y., Okubo, K., Olive-Elias, M., Ouedraogo, S., Paggiaro, P., Pali-Schöll, I., Palkonen, S., Panzner, P., Papi, A., Park, H.S., Passalacqua, G., Pedersen, S., Pereira, A.M., Pfaar, O., Picard, R., Pigearias, B., Pin, I., Plavec, D., Pohl, W., Popov, T.A., Portejoie, F., Postma, D., Poulsen, L.K., Price, D., Rabe, K.F., Raciborski, F., Roberts, G., Robalo-Cordeiro, C., Rodenas, F., Rodriguez-Mañas, L., Rolland, C., Roman Rodriguez, M., Romano, A., Rosado-Pinto, J., Rosario, N., Rottem, M., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G.K., Scichilone, N., Schmid-Grendelmeier, P., Serrano, E., Shields, M., Siroux, V., Sisul, J.C., Skrindo, I., Smit, H.A., Solé, D., Sooronbaev, T., Spranger, O., Stelmach, R., Sterk, P.J., Strandberg, T., Sunyer, J., Thijs, C., Triggiani, M., Valenta, R., Valero, A., Van Eerd, M., Van Ganse, E., Van Hague, M., Vandenplas, O., Varona, L.L., Vellas, B., Vezzani, G., Vazankari, T., Viegi, G., Vontetsianos, T., Wagenmann, M., Walker, S., Wang, D.Y., Wahn, U., Werfel, T., Whalley, B., Williams, D.M., Williams, S., Wilson, N., Wright, J., Yawn, B.P., Yiallouros, P.K., Yusuf, O.M., Zaidi, A., Zar, H.J., Zernotti, M.E., Zhang, L., Zhong, N., Zidarn, M., UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU-Pôle de Pneumologie, ORL et Dermatologie, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Foch [Suresnes], Universidade de Lisboa (ULISBOA), Service d'Allergologie pédiatrique [CHU Trousseau], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Sainte Perine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Crete [Heraklion] (UOC), Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Department of Respiratory Diseases, Aarhus University Hospital, University Children's Hospital Vienna, CHU Montpellier, IMIM-Hospital del Mar, Generalitat de Catalunya, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Operational Direction of Viral Diseases, Veterinary and Agrochemical Research Centre, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Edinburgh, Service de Pneumologie-Allergologie [Hôpital de la Timone - APHM], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Center for Public Health Research (CSISP), University of Valencia, Institut pour le développement sanitaire, Università degli studi di Torino (UNITO), Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Department of Paediatrics and Child Health, Faculty of Health Sciences, [et al.], University of Manitoba, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], University of Zürich [Zürich] (UZH), Hôpital Sainte-Périne-Rossini-Chardon Lagache, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universidade de Lisboa = University of Lisbon (ULISBOA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Unité de recherche de l'institut du thorax (ITX-lab), Università degli studi di Torino = University of Turin (UNITO), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Health Services Management & Organisation (HSMO), Internal Medicine, Pulmonary Medicine, Public Health, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Custovic, Adnan [0000-0001-5218-7071], Universidade do Minho, Hellings, P. W., Bergmann, K. C., Caimmi, D. P., Camargos, P. A. M., Canonica, G. W., Chavannes, N. H., Cruz, A. A., Fokkens, W. J., Guldemond, N. A., Naclerio, Marco, O'Hehir, R. E., Papadopoulos, N. G., Schunemann, H. J., Simons, F. E. R., Tomazic, P. V., Ventura, M. T., UMARAN YOUNG, CLARA ANDREA, Akdis, C. A., Ansotegui, I. J., Anto, J. M., Bateman, E. D., Bel, E. H., Bennoor, K. S., Białoszewski, A. Z., Boner, A. L., Boulet, L. P., Bousquet, P. J., Briggs, A. H., Brightling, C. E., Calderon, M. A., Carriazo, A. M., Carlsen, K. H., Cepeda Sarabia, A. M., Chirone, Mauro, Chuchalin, A. G., Chung, K. F., Dahlen, S. E., Denburg, J. A., Dinh-Xuan, A. T., Durham, S. R., Dykewicz, M. S., Gereda, J. E., Guzmán, M. A., Hourihane, J. O. B., Jares, E. J., Johnston, S. L., Jung, K. S., Kaidashev, I. P., Kalyoncu, A. F., Keith, P. K., Kerstjens, H. A. M., Koppelman, G. H., Kowalski, M. L., Le, L. T. T., Lodrup Carlsen, K. C., Macnee, W., Marshall, G. D., Masjedi, M. R., Meltzer, E. O., Mercier, Jeremy, Nyembue, T. D., Park, H. S., Pereira, A. M., Pohl, Walter, Popov, T. A., Poulsen, L. K., Rabe, K. F., Scadding, G. K., Sisul, J. C., Smit, H. A., Sterk, P. J., Varona, L. L., Wang, D. Y., Williams, D. M., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zernotti, M. E., Zhong, Xiao, and Çocuk Sağlığı ve Hastalıkları

Subjects
Pediatrics, AIRWAYS ICPs, ARIA, EIP on AHA, ICT, Mobile technology, Rhinitis, Immunology and Allergy, IMPACT, Hay fever, Respiratory Medicine and Allergy, Disease, Review, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 0302 clinical medicine, QUALITY-OF-LIFE, HDE ALER, Health care, Medicine and Health Sciences, PERSISTENT ALLERGIC RHINITIS, Medicine, 030212 general & internal medicine, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, AIRWAYS ICP, ComputingMilieux_MISCELLANEOUS, Rhiniti, Lungmedicin och allergi, Public Health, Global Health, Social Medicine and Epidemiology, 3. Good health, REAL-LIFE, CLINICAL-PRACTICE GUIDELINES, HEALTH, Pulmonary and Respiratory Medicine, medicine.medical_specialty, EUROPEAN INNOVATION PARTNERSHIP, Immunology, Socio-culturale, Clinical decision support system, Predictive medicine, 03 medical and health sciences, Quality of life (healthcare), Journal Article, Asma, Asthma, Science & Technology, business.industry, Settore MED/09 - MEDICINA INTERNA, AIRWAYS-ICPS, Correction, medicine.disease, 2008 UPDATE, Febre del fenc, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, 030228 respiratory system, Family medicine, VISUAL ANALOG SCALE, business
Abstract

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease., European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, EU Structural and Development Fund Languedoc-Roussillon, ARIA., info:eu-repo/semantics/publishedVersion

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results